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The remodeling response to extracellular matrix (ECM) scaffold materials such as porcine small 
intestinal submucosa (SIS) is characterized by intense mononuclear cell infiltration during the 
first 4 weeks post-implantation. Persistence of macrophages in wounds is typically diagnosed as 
chronic inflammation with downstream formation of scar tissue and/or foreign body reaction, but 
ECM scaffolds remodel into organized site-specific tissue. Macrophages can express either 
proinflammatory (M1) or immunomodulatory and tissue remodeling (M2) phenotypes. 
Processing methods used during the manufacturing of ECM scaffolds can influence macrophage 
phenotype and downstream remodeling outcome. 
In the first study, human monocyte-derived macrophages were cultured on SIS and 
carbodiimide (CDI) crosslinked SIS in 20% and 6% oxygen concentrations. Macrophage 
phenotype was evaluated by expression of M1 (CXCL10 and CCR7) and M2 (ARG-1, CCL13, 
CCL18, and MRC-1) gene markers, and secretion of CXCL10, CCL13, CCL18, and MMP9. 
Macrophages cultured on SIS expressed an M2 profile, while macrophages cultured on CDI-SIS 
expressed a mixed M1/M2 profile. No consistent patterns were observed when comparing 
oxygen concentrations. 
The second study used radioactive 14C-labeled scaffolds to measure ECM scaffold 
degradation in a rodent model of musculoskeletal reconstruction with and without the depletion 
of macrophages. Tissues were characterized by expression of M1 (iNOS and IFN-γ) and M2 
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(ARG-1 and IL-10) gene markers, and cell surface markers CD68 (pan-macrophage), CCR7 
(M1), and CD163 (M2). Results showed that macrophages are required for early and rapid 
degradation of SIS scaffolds, and that CDI-SIS is resistant to macrophage-mediated degradation. 
Furthermore, depletion of macrophages resulted in an attenuated inflammatory response and 
slowed the rate of scaffold degradation. 
The third study determined the contractile response and histomorphologic appearance of 
tissue repaired with SIS, CDI-SIS, or autologous tissue at 26 weeks after implantation. 
Contractile properties and fatigue resistance of remodeled tissue and of contralateral native tissue 
were assessed using an in-situ methodology. Muscle fiber-type distribution, blood vessel density 
and distribution, and innervation were determined. The tissue repaired with SIS showed 
complete replacement by tissue that histologically and functionally resembled native muscle. 
CDI-SIS was characterized by chronic inflammatory response and produced little to no 
measurable tetanic force output. 
 
 
 v 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................... XX 
1.0  NATURALLY OCCURRING EXTRACELLULAR MATRIX AS A BIOLOGIC 
SCAFFOLD MATERIAL ........................................................................................... 1 
1.1  MECHANISMS OF ECM SCAFFOLD REMODELING ................................... 3 
1.1.1  Importance of ECM Scaffold Degradation .................................................... 3 
1.1.2  Cellular Response ............................................................................................. 5 
1.1.2.1  Mononuclear Cell Response ................................................................. 5 
1.1.2.2  Recruitment of Progenitor Cells .......................................................... 5 
1.1.2.3  Maintenance of Differentiated Cell Phenotype .................................. 6 
1.1.3  Oxygen Diffusion .............................................................................................. 7 
1.1.4  Role of Mechanical Loading on ECM Remodeling ....................................... 8 
1.1.5  Summary ........................................................................................................... 9 
2.0  HOST RESPONSE TO SCAFFOLD MATERIALS .............................................. 11 
2.1  ROLE OF MACROPHAGES IN THE HOST RESPONSE .............................. 11 
2.1.1  Historical Perspective .................................................................................... 11 
2.1.2  Macrophage Phenotypes ................................................................................ 13 
2.2  CONSTRUCTIVE REMODELING VERSUS FOREIGN BODY RESPONSE
 .................................................................................................................................. 17 
2.2.1  Native (Non-crosslinked) ECM Scaffolds .................................................... 18 
 vi 
2.2.1.1  Lymphocyte Response ......................................................................... 19 
2.2.1.2  Macrophage Response ........................................................................ 20 
2.2.2  Chemically Crosslinked ECM Scaffolds ...................................................... 22 
2.2.2.1  Macrophage Response ........................................................................ 23 
2.3  SUMMARY ............................................................................................................. 24 
3.0  CENTRAL HYPOTHESIS AND SPECIFIC AIMS .............................................. 25 
4.0  SPECIFIC AIM 1:  TO DETERMINE THE PHENOTYPE OF 
MACROPHAGES FOLLOWING CONTACT WITH A BIOLOGIC 
SCAFFOLD COMPOSED OF SMALL INTESTINAL SUBMUCOSA .............. 28 
4.1  INTRODUCTION .................................................................................................. 28 
4.2  MATERIALS AND METHODS ........................................................................... 29 
4.2.1  Isolation and Preparation of Extracellular Matrix Scaffolds Derived from 
the Small Intestinal Submucosa (SIS) .......................................................... 29 
4.2.1.1  Preparation of SIS ............................................................................... 29 
4.2.1.2  Preparation of Carbodiimide crosslinked SIS-ECM ....................... 30 
4.2.2  Human Monocyte Isolation and Culture ..................................................... 30 
4.2.2.1  Differentiation of Monocytes into Macrophages .............................. 30 
4.2.2.2  Culture of Monocytes on SIS, CDI-SIS, or Tissue Culture Plastic 
(TCP) .................................................................................................... 31 
4.2.3  Scanning Electron Microscopy ..................................................................... 32 
4.2.4  mRNA Isolation and Quantitative Real Time RT-PCR Analysis .............. 32 
4.2.5  Measurement of DNA Content ..................................................................... 34 
4.2.6  Protein Analysis of Supernatant ................................................................... 35 
4.2.7  Nitric Oxide Analysis of Supernatant .......................................................... 35 
4.2.8  Statistical Methods ......................................................................................... 35 
 vii 
4.3  RESULTS ................................................................................................................ 36 
4.3.1  Crosslinking Efficacy ..................................................................................... 36 
4.3.2  Macrophage Morphology on Substrates ...................................................... 36 
4.3.3  Findings of mRNA Analysis .......................................................................... 41 
4.3.3.1  NOS2 and CXCL11 mRNA Expression ............................................. 41 
4.3.3.2  Donor-specific mRNA Expression of Monocytes ............................. 41 
4.3.3.3  mRNA Expression for M0, M1, and M2-induced Macrophages .... 42 
4.3.3.4  Effect of Substrate and Oxygen Tension on CXCL10 mRNA 
Expression ............................................................................................ 43 
4.3.3.5  Effect of Substrate and Oxygen Tension on CCR7 mRNA 
Expression ............................................................................................ 44 
4.3.3.6  Effect of Substrate and Oxygen Tension on ARG1 mRNA 
Expression ............................................................................................ 45 
4.3.3.7  Effect of Substrate and Oxygen Tension on CCL13 mRNA 
Expression ............................................................................................ 46 
4.3.3.8  Effect of Substrate and Oxygen Tension on CCL18 mRNA 
Expression ............................................................................................ 47 
4.3.3.9  Effect of Substrate and Oxygen Tension on MRC1 mRNA 
Expression ............................................................................................ 48 
4.3.3.10 Summary of mRNA Findings ............................................................. 49 
4.3.4  Findings of Protein Analysis ......................................................................... 50 
4.3.4.1  Protein Concentration Findings for M0, M1, and M2-induced 
Macrophages ........................................................................................ 50 
4.3.4.2  Effect of Substrate and Oxygen Tension on MMP9 Protein 
Concentration ...................................................................................... 51 
4.3.4.3  Effect of Substrate and Oxygen Tension on CXCL10 Protein 
Concentration ...................................................................................... 52 
 viii 
4.3.4.4  Effect of Substrate and Oxygen Tension on CCL13 Protein 
Concentration ...................................................................................... 53 
4.3.4.5  Effect of Substrate and Oxygen Tension on CCL18 Protein 
Concentration ...................................................................................... 54 
4.3.4.6  Summary of Protein Analysis ............................................................. 55 
4.3.5  Findings of Nitric Oxide Concentration Analysis ....................................... 56 
4.4  DISCUSSION .......................................................................................................... 56 
4.5  FUTURE STUDIES ................................................................................................ 58 
5.0  SPECIFIC AIM 2: TO DETERMINE THE NECESSITY OF PARTICIPATION 
OF MACROPHAGES FOR THE DEGRADATION OF SIS-ECM SCAFFOLDS
 ...................................................................................................................................... 60 
5.1  MATERIALS AND METHODS ........................................................................... 61 
5.1.1  Overview of Experimental Design ................................................................ 61 
5.1.2  Test Article Preparation ................................................................................ 62 
5.1.2.1  Preparation of 14C-SIS ........................................................................ 62 
5.1.2.2  Preparation of Carbodiimide Crosslinked 14C-SIS .......................... 64 
5.1.3  Animal Care Compliance .............................................................................. 64 
5.1.4  Experimental Animals and Husbandry ....................................................... 65 
5.1.5  Surgical Procedure ......................................................................................... 65 
5.1.6  In Vivo Macrophage Depletion ..................................................................... 67 
5.1.7  Euthanasia and Specimen Harvest ............................................................... 68 
5.1.8  Quantification of Degradation ...................................................................... 68 
5.1.9  Histology and Immunohistochemistry ......................................................... 69 
5.1.9.1  Antibodies ............................................................................................ 69 
5.1.9.2  Immunohistochemistry Procedure .................................................... 69 
 ix 
5.1.9.3  Quantitative Analysis of Macrophages ............................................. 70 
5.1.9.4  Analysis of M1/M2 Ratio .................................................................... 70 
5.1.9.5  Immunofluorescence ........................................................................... 71 
5.1.10  Gene Expression Analysis ............................................................................. 71 
5.1.10.1 RNA Isolation ...................................................................................... 71 
5.1.10.2 Quantitative Real Time RT-PCR. ...................................................... 72 
5.1.10.3 Gene Expression .................................................................................. 73 
5.1.11  Statistical Analysis ......................................................................................... 73 
5.2  RESULTS ................................................................................................................ 74 
5.2.1  Crosslinking Efficacy ..................................................................................... 74 
5.2.2  Surgical and Post-operative Outcomes ........................................................ 74 
5.2.3  Quantification of Degradation ...................................................................... 75 
5.2.4  Histopathologic Findings ............................................................................... 76 
5.2.4.1  Autologous Tissue Graft ..................................................................... 76 
5.2.4.2  14C-SIS Scaffold ................................................................................... 76 
5.2.4.3  14C-X-SIS Scaffold ............................................................................... 77 
5.2.5  Immunohistochemical Findings .................................................................... 79 
5.2.6  Gene Expression Findings ............................................................................. 83 
5.3  DISCUSSION .......................................................................................................... 87 
5.4  CONCLUSIONS ..................................................................................................... 89 
5.5  LIMITATIONS AND FUTURE WORK ............................................................. 90 
6.0  SPECIFIC AIM 3: TO DETERMINE THE HISTOMORPHOLOGY AND 
FUNCTIONALITY OF SIS-ECM SCAFFOLDS WHEN USED FOR THE 
RECONSTRUCTION OF MUSCULOSKELETAL TISSUE IN A RAT MODEL
 ...................................................................................................................................... 91 
 x 
6.1  INTRODUCTION .................................................................................................. 91 
6.2  MATERIALS AND METHODS ........................................................................... 92 
6.2.1  Overview of Experimental Design ................................................................ 92 
6.2.2  Test Articles .................................................................................................... 93 
6.2.3  Animal Care Compliance .............................................................................. 93 
6.2.4  Animal Source and Husbandry .................................................................... 93 
6.2.5  Surgical Procedure ......................................................................................... 94 
6.2.6  Measurement of Contractile Force In-Situ .................................................. 95 
6.2.6.1  Muscle Flap Preparation .................................................................... 95 
6.2.6.2  Contractile Force Testing ................................................................... 97 
6.2.6.3  Fatigue Resistance Testing ................................................................. 97 
6.2.7  Euthanasia and Specimen Harvest ............................................................... 97 
6.2.8  Histologic and Immunohistochemical Analysis ........................................... 98 
6.2.9  Statistical Analysis ....................................................................................... 100 
6.3  RESULTS .............................................................................................................. 100 
6.3.1  Contractile Properties of Remodeled Tissue ............................................. 100 
6.3.2  Histomorphologic and Immunolabeling Findings .................................... 104 
6.3.2.1  Native tissue ....................................................................................... 104 
6.3.2.2  Restore device .................................................................................... 105 
6.3.2.3  CuffPatch device ................................................................................ 106 
6.3.2.4  Autologous tissue graft ...................................................................... 107 
6.4  DISCUSSION ........................................................................................................ 110 
6.5  CONCLUSION ..................................................................................................... 114 
 xi 
6.6  LIMITATIONS AND FUTURE WORK ........................................................... 114 
7.0  DISSERTATION SYNOPSIS ................................................................................. 116 
APPENDIX A ............................................................................................................................ 118 
BIBLIOGRAPHY ..................................................................................................................... 136 
 xii 
 LIST OF TABLES 
Table 1: A partial list of ECM products commercially available for human clinical use. ............. 2 
Table 2: Sequences of Human-Specific Primer Sets Used in Real Time Analysis ...................... 34 
Table 3: Genes differentially expressed in M1 vs. M2 macrophages. .......................................... 43 
Table 4: Proteins differentially expressed in M1 vs. M2 macrophages. ....................................... 51 
Table 5: Sequences of Rat-Specific Primer Sets Used in Real Time Analysis ............................ 72 
Table 6: Quantification of 14C-SIS and 14C-X-SIS Scaffold Degradation, as Measured by LSC 75 
Table 7: The contractile properties for each scaffold group and the contralateral native tissue. 103 
Table 8: Quantitative IHC analysis for each scaffold group and the contralateral native tissue 110 
Table 9: Source tissue, configuration, and processing methods for each of the five commercially 
available ECM materials. ............................................................................................................ 120 
Table 10: Scoring criteria of the semiquantitative histological analysis*. ................................. 123 
Table 11: Mean rounded scores for each group according to time-treatment combination*. .... 126 
 xiii 
LIST OF FIGURES 
Figure 1: Inducers, secreted products, and functional properties of macrophage populations 
polarized toward either an M1 phenotype or an M2 phenotypes. Reprinted from [108], with 
permission from Elsevier. ............................................................................................................. 15 
Figure 2: Schematic of the L-arginine pathway. Reproduced with permission from [122], the 
Biochemical Society [http://www.biochemsotrans.org] ............................................................... 16 
Figure 3: The macrophage polarization percentages for (A) SIS and (B) carbodiimide crosslinked 
SIS (CDI-SIS) at 1 (white bars), 2 (light grey bars), 4 (dark grey bars), and 16 (black bars) weeks 
post-implantation in a rodent model of musculoskeletal repair. Mean ± standard error of the 
mean; *p < 0.001 and #p < 0.03. Reproduced from [60], with permission from Liebert 
Publishing. .................................................................................................................................... 21 
Figure 4: Masson’s trichrome staining at 16 weeks post-surgery in a rodent model of 
musculoskeletal repair. (A) Photomicrograph of completely remodeled SIS device. Blood 
vessels, scattered skeletal muscle fibers, and organized collagen completely replaced the SIS 
device (100X). (B) Photomicrograph of carbodiimide crosslinked SIS device. A dense 
mononuclear cell response can be observed with the presence of multinucleate giant cells 
(arrows) and fibrosis around the scaffold material (400X). Reproduced from [60], with 
permission from Liebert Publishing.............................................................................................. 22 
Figure 5: Schematic of culture conditions. ................................................................................... 32 
Figure 6: Comparison of morphologic appearance of M1 and M2-differentiated macrophages at 
168 hours in 20% and 6% oxygen concentrations. ....................................................................... 37 
Figure 7: Comparison of morphologic appearance of macrophages on the luminal surface of SIS 
at 18, 72, and 168 hours in 20% and 6% oxygen concentrations. ................................................ 38 
Figure 8: Comparison of morphologic appearance of macrophages on the luminal surface of 
CDI-SIS at 18, 72, and 168 hours in 20% and 6% oxygen concentrations. ................................. 39 
Figure 9: Comparison of morphologic appearance of macrophages on glass coverslips in 
complete media only at 18, 72, and 168 hours in 20% and 6% oxygen concentrations. .............. 40 
Figure 10: Baseline threshold cycle for each gene was subtracted from the threshold cycle for the 
housekeeping gene (ΔCt) from each donor of the isolate monocytes (Mono-#). ......................... 41 
 xiv 
Figure 11: mRNA expression for M0, M1, and M2-induced macrophages cultured in 20% and 
6% oxygen. ................................................................................................................................... 42 
Figure 12: CXCL10 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 
18, 72, and 168 hours in 20% and 6% oxygen. ............................................................................. 44 
Figure 13: CCR7 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 
72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a scaffold group. .............................................................................................. 45 
Figure 14: ARG1 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 
72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group. ............................................................................................. 46 
Figure 15: CCL13 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 
72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group, and ‡ indicates statistical significance between substrate 
groups within a timepoint. ............................................................................................................ 47 
Figure 16: CCL18 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 
72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group. ............................................................................................. 48 
Figure 17: MRC1 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 
72, and 168 hours in 20% and 6% oxygen.................................................................................... 49 
Figure 18: Protein levels in supernatants from M0, M1, and M2-induced macrophages at 168 
hours in 20% and 6% oxygen. ...................................................................................................... 50 
Figure 19: Concentration of MMP9 in supernatants from macrophages cultured on SIS, CDI-SIS, 
and TCP at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 
0.05) between timepoints within a substrate group. ..................................................................... 52 
Figure 20: CXCL10 concentration in supernatants from macrophages cultured on SIS, CDI-SIS, 
and TCP at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 
0.05) between timepoints within a substrate group, and ‡ indicates statistical significance 
between substrate groups within a timepoint. ............................................................................... 53 
Figure 21: Concentration of CCL13 in supernatants from macrophages cultured on SIS, CDI-
SIS, and TCP at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance 
(p < 0.05) between timepoints within a substrate group, and ‡ indicates statistical significance 
between substrate groups within a timepoint. ............................................................................... 54 
Figure 22: Concentration of CCL18 in supernatants from macrophages cultured on SIS, CDI-
SIS, and TCP at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance 
 xv 
(p < 0.05) between timepoints within a substrate group, and ‡ indicates statistical significance 
between substrate groups within a timepoint. ............................................................................... 55 
Figure 23: Counts of 14C per minute per gram of labeled porcine tissues using liquid scintillation 
counting. The more metabolic tissues (aorta, liver, small intestine) tended to have higher levels 
of 14C at approximately 3500 CPM/g. Reprinted from [64], with permission from Elsevier. ...... 63 
Figure 24: Schematic and histological depiction of the partial thickness abdominal wall defect 
model (Masson’s trichrome, 40X). ............................................................................................... 67 
Figure 25: Representative images of autologous, 14C-SIS, and 14C-X-SIS scaffold implantation 
sites 2 weeks post-implantation. Graft sites from animals treated with clodronate liposomes 
showed almost no scaffold degradation. Graft sites from animals treated with PBS liposomes or 
saline show dense accumulations of mononuclear cells for all graft types and scaffold 
degradation for the autologous and 14C-SIS scaffolds. Arrows point to muscle cells that remained 
in the autologous tissue graft site. For the 14C-SIS and 14C-X-SIS scaffolds, asterisks (*) indicate 
the layers of the original multilaminate scaffolds that remain in the implantation site. Sections 
were stained with H&E. Scale bar = 100 μm. ............................................................................... 78 
Figure 26: CD68+ cells per 400X field, 10 fields per graft site, examined at the host-implant 
interface. Data represent mean ± SD. *Significant compared with PBS liposome control (p < 
0.001); #significant compared with saline control (p < 0.001). .................................................... 79 
Figure 27: Immunofluorescent images of scaffold sites 2 weeks post-implantation from animals 
that received IV injections of DiI-labeled PBS liposomes. The distribution of DiI-labeled cells 
(red), CD68+ macrophages (Alexafluor 488, green), and cell nuclei (DAPI, blue) are shown in 
merged images. Scale bar = 100 μm. ............................................................................................ 80 
Figure 28: Representative photomicrographs of immunohistochemical staining for CD68 (pan 
macrophages), CCR7 (M1 macrophages), and CD163 (M2 macrophages) in autologous, 14C-SIS, 
and 14C-X-SIS scaffold repair sites from saline-treated animals at one week post-surgery. Scale 
bar = 300 μm. ................................................................................................................................ 81 
Figure 29: Percentage macrophage polarization at one and two weeks post-implantation of (A) 
autologous, (B) 14C-SIS, and (C) 14C-X-SIS scaffolds. All values are presented as mean ± SEM. 
For the percent of M1 cells, no statistically significant effects were found. For the percent of M2 
cells, the statistically significant effects were the scaffold by time interaction (P < 0.03). (D) The 
percentage of M1 (CCR7+) macrophages was subtracted from the percentage of M2 (CD163+) 
macrophages for each scaffold and treatment group at one and two weeks post-implantation. 
Positive values are indicative of an M1 type response while negative values are indicative of an 
M2 type response. ......................................................................................................................... 83 
Figure 30: Gene expression of iNOS and ARG-1 relative to the housekeeping gene and the native 
abdominal muscle at one and two weeks post implantation of (A) autologous, (B) 14C-SIS, and 
(C) 14C-X-SIS scaffolds. All values are presented as mean ± SEM. * indicates statistical 
significance (p < 0.05) within a scaffold group. ‡ indicates statistical significance (p < 0.05) 
 xvi 
between scaffold groups within a treatment group. (D) Ratio of iNOS:ARG-1 expression for each 
scaffold and treatment group at one and two weeks post-implantation. Values above 1.0 are 
indicative of a predominance of iNOS expression while values less than 1.0 are indicative of a 
predominance of ARG-1 expression. ............................................................................................ 85 
Figure 31: Gene expression of (A) IFN-γ and (B) IL-10 relative to the housekeeping gene and the 
native abdominal muscle one and two weeks post-implantation for autologous, 14C-SIS, and 14C-
X-SIS scaffolds. All values are presented as mean ± SEM. * indicates statistical significance (p < 
0.05) within a scaffold group. ‡ indicates statistical significance (p < 0.05) between scaffold 
groups within a treatment group. .................................................................................................. 86 
Figure 32: Representative schematic of the apparatus used to measure in situ tetanic force 
generation. Top illustration: the musculoskeletal defect was created by excising the external and 
internal oblique layers of the abdominal wall, leaving the transversalus fascia intact. Middle 
illustration: the test article was implanted in the defect site and secured with Prolene sutures at 
each of the four corners. Bottom illustration: twenty-six weeks post-implantation, a flap of tissue 
was created which contained the site of test article placement, identified by the preplaced Prolene 
sutures. The tissue flap maintained the muscular arteries and the thoracic spinal nerve branches 
that supplied the site of tissue remodeling. The muscle fibers on the remaining sides of the 
implantation site, including the insertion site at the linea alba, were dissected free from the 
surrounding adjacent tissue. The distal end of the flap was connected to the force transducer with 
silk suture, and positioned such that the direction of the function testing was aligned parallel to 
the rib origin. Platinum electrodes were placed across the flap proximal and distal to the scaffold 
placement site. ............................................................................................................................... 96 
Figure 33: In situ muscle contraction studies were performed on muscle flaps from implants at 
26 weeks post-surgery and compared to contralateral, native muscle. The tetanic forces (N) 
generated by remodeled and native tissue following electrical stimulation between 5 and 75 pps. 
Data expressed as mean ± standard error. ................................................................................... 101 
Figure 34: The percent tetanic force of the remodeled tissue compared to the contralateral native 
tissue with respect to the tetanic force at each stimulation frequency. Data expressed as mean ± 
standard error. ............................................................................................................................. 102 
Figure 35: The percent tetanic force of the remodeled tissue compared to the contralateral native 
tissue with respect to the maximum tetanic force. Data expressed as mean ± standard error. ... 102 
Figure 36: Contractile forces (N/cm2) of tissue, which peaked at 40 pps for the native tissue, and 
50 pps for the remodeled tissue. Data expressed as mean ± standard error. ............................... 103 
Figure 37: At 26 weeks post surgery, the native tissue was composed mainly of muscle cells 
organized into tight bundles and mature blood vessels and nerves (arrows) were adjacent to the 
muscle bundles. Tissue sections were stained with Masson’s trichrome. Higher magnification 
image was acquired from the lower magnification image in the area outlined by the rectangle. 
Scale bars = 300 μm. ................................................................................................................... 104 
 xvii 
Figure 38: At 26 weeks post implantation, the Restore device completely remodeled into new 
host tissue which was comprised of bundles of muscle fibers surrounded by vascularized, 
organized collagenous connective tissue. Tissue sections were stained with Masson’s trichrome. 
Higher magnification image was acquired from the lower magnification image in the area 
outlined by the rectangular. Scale bars = 300 μm. ...................................................................... 105 
Figure 39: After 26 weeks post surgery, the tissue treated with the CuffPatch device contained 
identifiable remnants of the originally implanted device (*), which were surrounded by dense 
collagenous tissue, numerous blood vessels, and inflammatory cells including multinucleate 
giant cells. Tissue sections were stained with Masson’s trichrome. Higher magnification image 
was acquired from the lower magnification image in the area outlined by the rectangle. Scale 
bars = 300 μm. ............................................................................................................................ 106 
Figure 40: At 26 weeks post surgery, the tissue treated with the autologous graft showed 
randomly dispersed muscle bundles surrounded by fibrous connective tissue and adipose 
connective tissue. Tissue sections were stained with Masson’s trichrome. Higher magnification 
image was acquired from the lower magnification image in the area outlined by the rectangle. 
Scale bars = 300 μm. ................................................................................................................... 107 
Figure 41: Blood vessel distribution and innervation of native and remodeled tissue. Tissue 
sections at 26 weeks post surgery were immunolabeled for Von Willibrand Factor to identify 
endothelial cells associated with the lumen of blood vessels (A-D), and anti-neurofilament was 
used to identify nerve structures (E-H) in the native and remodeled tissue sections. Mature blood 
vessels (A) and nerves (E) were located adjacent to the muscle bundles for the native tissue. The 
tissue repaired with the Restore device (B,F), and the tissue repaired with the autologous graft 
(D,H) showed nerves adjacent to the new muscle cells, and larger blood vessels were identified 
throughout the implantation site. The remnants of the original CuffPatch device (indicated by *) 
(C) were surrounded by a substantial amount of capillaries and larger vessels; individual neurons 
were located in close proximity to new blood vessels that surrounded the remnants of the 
CuffPatch device (G). Scale bars = 300 μm. .............................................................................. 108 
Figure 42: Distribution of slow and fast skeletal muscle fibers in native tissue and remodeled 
tissue at 26 weeks post surgery. Tissue sections were double-labeled for antimyosin slow (type I) 
skeletal muscle (brown stain) and antimyosin fast (type II) skeletal muscle (red stain). The native 
tissue (A) and the tissue repaired with the Restore device (B) showed that the slow muscle fibers 
were uniformly distributed between the fast muscle fibers. Skeletal muscle fibers surrounded the 
proximal edges of the CuffPatch device (C) but were not located within the graft site. (D) In the 
autologous tissue graft, the slow muscle fibers were distributed in an irregular pattern among the 
fast muscle fibers in the remodeling site, in that the slow fibers were sporadically distributed in 
some areas and arranged in clusters for other areas. Scale bars = 300 μm. ................................ 109 
Figure 43: Histologic appearance of the autologous tissue graft at (A) seven and (B) 112 days. At 
seven days, necrotic skeletal muscle fiber bundles (*), a dense infiltration of neutrophils, and 
mononuclear cells were present. At 112 days the autograft was replaced by moderately dense 
scar tissue, characterized by fibrous connective tissue and adipose connective tissue. The red-
 xviii 
staining muscle fibers at the bottom of the image represent the underlying transversalis 
(Masson’s trichrome, X200, insets, X400). ................................................................................ 127 
Figure 44: Histologic appearance of the GraftJacket device (stained blue) at (A) seven and (B) 
112 days after surgery. At seven days, a dense mononuclear cell infiltration was limited almost 
exclusively to the edge of the device (arrows). Inset: The arrow represents the lower edge of the 
GraftJacket-host tissue interface, which is bordered by dense, red-staining mononuclear cell 
infiltrate. At 112 days, there was partial degradation of the GraftJacket device, with replacement 
by moderately organized dense collagenous connective tissue. The original device is marked 
with *, and newly deposited collagenous connective tissue is marked with an arrow (Masson’s 
trichrome, X200, insets, X400). .................................................................................................. 129 
Figure 45: Histologic appearance of the Restore device (A) seven and (B) 112 days after surgery. 
At seven days, a dense mononuclear cell infiltration separated the individual layers of the device 
(blue-staining material marked with *). At 112 days, the Restore device had been replaced by a 
vascularized connective tissue with islands of skeletal muscle scattered randomly throughout the 
tissue (arrows) (Masson’s trichrome, X200, insets, X400). ....................................................... 130 
Figure 46: Histologic appearance of the CuffPatch device at (A) seven and (B) 112 days post 
implantation. At seven days, a dense accumulation of neutrophils and mononuclear cells were 
located primarily at the edge of the implanted device (the arrows indicate the edge of CuffPatch, 
the blue-stained material). The native abdominal wall skeletal muscle tissue can be seen in the 
lower left-hand portion. Inset: The interface between the dense cellular accumulation and the 
edge of the CuffPatch device. 112 days, there were a moderate number of inflammatory cells, 
including multinucleate giant cells (arrow) within the graft site. Remnants of the originally 
implanted CuffPatch device could still be identified (blue material marked with *) (Masson’s 
trichrome, X200, insets, X400). .................................................................................................. 132 
Figure 47: Histologic appearance of the TissueMend device at (A) seven and (B) 112 days after 
implantation. At seven days, there was very little infiltration of the edge of the device by host 
inflammatory cells (the arrows show the lower edge of the TissueMend, the solid blue-stained 
material). At 112 days, the device-implant site showed an accumulation of adipose connective 
tissue (circular white areas) at the edges of the TissueMend device (internal to the surrounding 
capsule, as indicated by the bracket), but the remainder of the device (blue materials marked with 
*) remained virtually unchanged from the time of implantation (Masson’s trichrome, X200, 
insets, X400). .............................................................................................................................. 133 
Figure 48: Histologic appearance of the Permacol device at (A) seven and (B) 112 days after 
surgery. At seven days, there was an accumulation of both neutrophils and mononuclear cells 
mixed with a thin fibrous capsule surrounding the device. The solid blue-staining material above 
the horizontal line is the Permacol device. Inset: Inflammatory cells at the periphery of the 
Permacol device (*). At 112 days, a dense fibrous tissue (brackets) encapsulates the Permacol 
device (blue staining material located above the bracket). There was almost no evidence of 
scaffold degradation or remodeling (Masson’s trichrome, X200, insets, X400). ....................... 134 
 xix 
PREFACE 
Throughout my graduate school career and during the completion of my Dissertation, I have 
been blessed by countless individuals who have helped shape me into the scientist that I am 
today. I wish to extend my immense gratitude to Dr. Stephen Badylak, who took a chance on a 
Florida Gator and provided a structured, intense, and challenging mentorship in the 
multidiscipline field of tissue engineering and regenerative medicine. Dr. Badylak provided all 
the tools and personnel in a world-class laboratory setting that enabled infinite opportunities and 
growth of scientific creativity. I owe immense gratitude to the members of the Badylak 
Laboratory – past and present – who have supported me from conception to completion of my 
Dissertation. I have been privileged to work with passionate and intelligent scientists, including 
Dr. Ann Stewart-Akers, Dr. Thomas Gilbert, Dr. Danny Freytes, and Jennifer DeBarr, who have 
been very supportive professionally and personally.  
Thank you to all of my wonderful friends, who have enriched my life with the blessings 
of unconditional love, belief in my capabilities, and have given me a lighter heart when things 
were difficult: Rebecca Mayton, Lisa MacDonald, Jennifer Engleson, to name a few.  
I could not have survived without the support and love of my family: my husband Dimas, 
my mother Roberta Hodge, and my most inspirational angel of all, my daughter Elizabeth Maria. 
Thank you for providing a rock-solid ground for me to stand on, a shoulder to lean on, and words 
of wisdom to inspire me. I also want to thank my God and Savior Jesus Christ, whom I owe my 
life and accomplishments during the most challenging and soul-searching time of my life.  
 xx 
ACRONYMS 
 
14C   Carbon 14 
ARG1   Arginase Type 1 
BSA   Bovine Serum Albumin 
CCL   Chemokine (C-C Motif) Ligand    
CCR   Chemokine (C-C Motif) Receptor 
CD   Cluster of Differentiation 
CDI   Carbodiimide 
CPM   Counts per Minute 
CXCL   Chemokine (C-X-C Motif) Ligand 
DAB   Diaminobenzidine 
ECM   Extracellular Matrix 
ELISA   Enzyme-Linked ImmunoSorbent Assay 
GM-CSF  Granulocyte Macrophage Colony Stimulating Factor 
H&E   Hematoxylin and Eosin 
IFN-γ   Interferon-gamma 
Ig   Immunoglobulin 
IL   Interleukin 
iNOS, NOS2  Inducible Nitric Oxide Synthase Type 2 
IV   Intravenous 
LPS   Lipopolysaccharide 
LSC   Liquid Scintillation Counting 
 xxi 
 xxii 
M1   Type 1 Macrophage 
M2   Type 2 Macrophage 
M-CSF  Macrophage Colony Stimulating Factor 
MMP   Matrix Metalloproteinase 
MRC1   Mannose Receptor C Type 1 
NBF   Neutral Buffered Formalin 
NO   Nitric Oxide 
PBMC   Peripheral Blood Mononuclear Cells 
PBS   Phosphate Buffered Saline 
Rh   Recombinant Human 
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction 
SEM   Scanning Electron Microscopy 
SIS   Small Intestinal Submucosa 
TBS   Tris Buffered Saline 
TGF-β   Transforming Growth Factor-beta 
Th   Helper T-cells 
TNF-α   Tumor Necrosis Factor-alpha 
VEGF   Vascular Endothelial Growth Factor 
UBM   Urinary Bladder Matrix
1.0  NATURALLY OCCURRING EXTRACELLULAR MATRIX AS A BIOLOGIC 
SCAFFOLD MATERIAL 
Tissue engineering and regenerative medicine approaches to tissue reconstruction include the use 
of scaffolding materials composed of mammalian extracellular matrix (ECM) to promote cell 
attachment, migration, proliferation, and spatial organization [1-8]. Naturally occurring ECM 
scaffolds remodel into functional tissues in numerous preclinical and clinical studies, including 
dermal [9-14], cardiac [15-20], gastroesophageal [21-23], urological [24-30], and 
musculotendinous [31-42] applications. The purported advantages of using ECM-derived 
scaffolds include their natural three-dimensional ultrastructure and their diverse composition of 
structural and functional proteins, including collagen, elastin, growth factors, and proteoglycans 
[3, 43-52]. During the past decade, off-the-shelf biologic scaffold materials composed of ECM 
have become available for the repair and reconstruction of damaged or missing tissues (Table 1). 
These ECM-based products differ in the species of origin (e.g., human, bovine, equine, or 
porcine), tissue source (e.g., dermis, fascia lata, pericardium, or small intestine), and the 
processing techniques used to prepare each device for human clinical use. The marketing 
literature for these devices may claim host acceptance and intact functionality; however, there 
usually are marked differences in the amount and temporal appearance of inflammatory cells, the 
morphologic structural integrity of the devices over time, and the type of host tissue that replaces 
or surrounds the ECM devices (Appendix A). It is not clear how these differences can alter the 
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host tissue remodeling response, but the temporal sequence of remodeling events, including the 
rapidity of scaffold degradation and extent of new tissue deposition, would logically be 
predictive of the functional outcome. 
 
Table 1: A partial list of ECM products commercially available for human clinical use. 
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1.1 MECHANISMS OF ECM SCAFFOLD REMODELING 
Biologic scaffolds composed of ECM can promote the site-appropriate tissue reconstruction of 
injured tissues through mechanisms that include angiogenesis [5, 22, 28, 46, 48], the recruitment 
of multipotential progenitor cells to the site of tissue reconstruction [2, 7, 8, 53], the release of 
antimicrobial peptides [16, 19, 54-57], and activation of the alternative pathway of immunity 
[58-62]. There is convincing evidence that host-mediated degradation of ECM scaffolds is 
typically completed within eight to twelve weeks and is necessary to realize the full beneficial 
effects of ECM-mediated tissue remodeling [40, 42, 63], but the mechanisms by which such 
scaffold degradation occurs have been largely ignored. Further work is needed to better 
understand the cellular mechanisms of biologic scaffold remodeling and to correlate such 
findings with the methods by which the materials are processed and with the eventual clinical 
outcome. This thesis examines the role and phenotype of macrophages involved in the 
degradation and “processing” of scaffold materials, and investigates the relationship between 
early remodeling events and downstream characteristics of the remodeled scaffold materials. 
1.1.1 Importance of ECM Scaffold Degradation 
The evaluation of scaffold degradation is usually based on the histomorphologic appearance of 
the implantation site and the ability of the investigator to recognize intact devices. Unless 
molecular or radioactive labeling of the devices is performed to quantify the rate of scaffold 
degradation, it is possible that remnants of the remodeled scaffold materials remain at the site 
and are incorporated into the new host tissue even when histologic evaluation fails to recognize 
their presence. The only scaffold material for which quantitative data exists for in vivo 
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degradation is the non-crosslinked form of small intestinal submucosa (SIS). Those studies used 
carbon 14 (14C)-proline to radiolabel the total collagen content of SIS to quantitatively determine 
the rate of degradation and to track the fate of the degradation products of SIS scaffolds 
following placement in canine models of Achilles tendon and urinary bladder repair [40, 63]. 
The 14C-labeled SIS materials showed approximately 50% degradation by 20 days and complete 
elimination and concomitant replacement with host cells and new ECM deposition by 60-90 days 
[63, 64]. 
Rapid degradation emphasizes the importance placed upon the source and type of cells 
that must populate the scaffold, secrete new ECM, and participate in tissue remodeling. Also 
significant to the remodeling process, molecules that are encoded or bound within the cryptic 
sites of the matrix are released upon structural or compositional changes to the ECM parent 
molecules [65], and these low molecular weight ‘matricryptic’ fragments, in concert with other 
signals such as growth factors, have biologic activity such as chemoattractant activity for 
primary endothelial cells, bone marrow-derived cells, multipotential progenitor cells, 
inflammatory cells, and other cell types [2, 5, 7, 66, 67]. The degradation products of ECM 
scaffolds also show mitogenic activity for progenitor cells [7] and antimicrobial activity against 
Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus [16, 19, 54-56, 68]. In 
clinical applications, non-crosslinked ECM scaffolds are the only grafts that are indicated for 
contaminated wounds because of the antibacterial effects associated with their degradation [68]. 
At least a portion of the host biologic response to ECM-derived materials is associated with 
and/or caused by the degradation products of the scaffold itself. Conversely, the lack of 
degradation of a biologic scaffold material would logically suggest that such downstream effects 
would not occur.  
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1.1.2 Cellular Response 
1.1.2.1 Mononuclear Cell Response 
Mononuclear cells are commonly observed and are expected participants in the host response to 
all biomaterials, including those that are used as scaffolds for tissue reconstruction. The term 
“mononuclear cell’ is a generic morphologic description for a population of cells with a single 
nucleus, usually having a round or oblong shape, and variable amounts of cytoplasm. 
Mononuclear cells are typically associated with phagocytic capability, and are assumed to 
participate in chronic inflammation with downstream consequences of necrosis, fibrosis with 
encapsulation, some degree of scar tissue formation, or a combination of the three [69, 70]. A 
variety of cell types are virtually indistinguishable upon routine examination of peripheral blood 
or tissue sections, although various progenitor cells [71-78], circulating fibrocytes [79-82], blood 
monocytes [83], and others [84-86] fit the morphologic description of a classic mononuclear cell. 
Clearly, the conventional term ‘mononuclear cell’ is not always sufficient to fully describe the 
host response of ECM scaffolds or predict the eventual tissue remodeling outcome. 
1.1.2.2 Recruitment of Progenitor Cells 
ECM scaffolds including SIS are capable of inducing site-specific remodeling with differentiated 
tissue structures such as skeletal [35, 42] and smooth muscle [27], myocardium [17], specialized 
epithelium [21, 22], and well-organized connective tissue [8, 32, 40]. Recent studies have shown 
that bone marrow-derived progenitor cells are recruited to the site of ECM remodeling and 
participate in the differentiation of site-appropriate tissue structures [8, 53]. A percentage of 
these bone marrow progenitor cells differentiate into functional cells that secrete collagen and 
remain in the remodeled tissue after inflammation has subsided [8].  Beattie and colleagues 
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investigated the chemotactic properties of tissue harvested during the first 14 days after repair 
with a urinary bladder matrix (UBM) ECM scaffold in a murine model of Achilles tendon 
reconstruction [2]. The results showed that multipotential progenitor cells (MRL blastema cells 
[7]) preferentially migrated toward the tendons repaired with UBM compared to tendons repaired 
with autologous tissue or uninjured normal tendons. The recruitment of progenitor cells toward 
degrading ECM scaffolds is an area of scientific interest in understanding the mechanisms for 
constructive remodeling. 
1.1.2.3 Maintenance of Differentiated Cell Phenotype 
The ultrastructure of ECM is synthesized and continually maintained by the resident cell 
population of most tissues and organs, and serves to support and direct cells in a highly defined 
and specialized microenvironment [67, 87-89]. A variety of cell types, including NIH 3T3 
fibroblasts [90], primary human bladder urothelial and smooth muscle cells [91], primary 
tracheal chondrocytes and epithelial cells [unpublished data], human pancreatic islets [92], and 
primary human epidermal cells [6], maintain tissue-specific phenotypes when cultured on the 
surface of scaffold materials derived from ECM. Sellaro et al. demonstrated that hepatic 
sinusoidal endothelial cells (SECs) co-cultured with hepatocytes on the surface of materials 
composed of liver-derived ECM maintained a differentiated phenotype to a greater degree and 
for a longer duration of culture than substrates composed of purified collagen type I, or ECM 
derived from the urinary bladder (UBM) or small intestinal submucosa (SIS) [87]. This study 
suggests that for some cell populations such as SECs the origin of the tissue or organ from which 
the ECM is derived may make a significant difference in the modulation or maintenance of 
specialized phenotypes. It is evident that ECM scaffolds are more suitable for supporting tissue-
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specific phenotypes for differentiated cells compared to scaffolds composed of individual 
components of ECM such as collagen. 
1.1.3 Oxygen Diffusion 
The passive diffusivity of oxygen through a biomaterial is one of many factors associated with 
cell viability, metabolic activity, and the rapidity with which cells can successfully populate a 
scaffold material. The amount of oxygen available to the remodeling site will be determined by 
the surrounding microenvironment including the local vascular network. At the time of surgical 
placement of a biomaterial, the existing vasculature is limited to the outer boundaries; a factor 
which likely slows cell migration into the scaffold in the early stages of remodeling and has an 
effect on cell behavior due to a hypoxic environment [93]. A study by Valentin et al. showed that 
oxygen diffusion through ECM materials is at least partially dependent on the complexity of the 
collagen fiber arrangement and ultrastructure, including the presence of a basement membrane 
[94]. Oxygen diffusivity would logically become less important as scaffold remodeling proceeds 
with the deposition of plasma proteins, the secretion of host neo-ECM, the population of host 
cells occupying the material, and the development of new vascular networks. Stated differently, 
the remodeling characteristics after ECM scaffold implantation may be partially attributed to the 
ability of the biologic material to diffuse oxygen in the early stages of the host response, coupled 
with relatively rapid degradation, and subsequent release of angioinductive matrix-bound growth 
factors. It has been shown that component growth factors such as vascular endothelial growth 
factor (VEGF), transforming growth factor-beta (TGF-β), and basic fibroblast growth factor 
(bFGF) are incorporated within SIS and that active forms of these factors survive the processing 
and terminal sterilization steps that are used to disrupt cell membranes and cytoplasmic 
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organelles, denature cytoplasmic proteins, and largely eliminate these components from the 
remaining ECM [4, 48, 49, 95, 96]. These growth factors are released during scaffold 
degradation and stimulate angiogenesis, mitogenesis, and cellular differentiation during tissue 
remodeling. Biologic scaffold devices composed of ECM material other than SIS may also retain 
growth factor activity following device preparation, but few published studies to that effect are 
available [51].  
1.1.4 Role of Mechanical Loading on ECM Remodeling 
The physical properties of scaffold materials prior to implantation are important determinants of 
clinical success, and are usually used as predictors of the clinical utility of the device. Equally if 
not more important however, is the change in the physical properties of the scaffold during the 
remodeling process. The degradation rate of non-chemically crosslinked ECM appears to be 
compatible with the rate of new host tissue deposition, such that the scaffold retains sufficient 
strength to serve as a functional replacement until the host can deposit new host tissue [17, 35, 
38, 97]. However, there is a measureable loss of strength that occurs prior to transfer of 
mechanical function to the new host tissue. For Achilles tendon [98], medial collateral ligament 
[31, 99], abdominal body wall [97], urinary bladder [27, 100], and esophageal [21] repair, the 
strength of non-crosslinked ECM scaffolds decreased as a result of scaffold degradation, but the 
mechanical properties of the new host tissue subsequently increased to anatomically site 
appropriate levels when mechanical load was applied from the onset of scaffold placement.  
A study by Boruch et al. utilized a canine model of partial cystectomy to demonstrate the 
importance of physiologic biomechanical load to constructive remodeling [27]. A defect was 
created in the anterior dome of the urinary bladder and repaired with either an SIS or UBM 
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scaffold. The animals were then divided according to the duration of post-operative 
catheterization. The bladders from animals that received an indwelling catheter for 28 
consecutive days post-surgery showed evidence of contraction and a lack of urothelization at the 
site of scaffold placement. The bladders from animals that received the catheter for only 24 hours 
post-surgery demonstrated a constructive host remodeling response, characterized by complete 
urothelialization along the luminal surface, vascularity, innervation, and islands of smooth 
muscle bundles. This study showed that exposure of ECM scaffolds to a physiologic-appropriate 
pattern of mechanical loading (cyclic distention) promoted constructive remodeling. In a similar 
fashion, a study that utilized a rabbit model of Achilles tendon repair ascertained that joint 
immobilization during the remodeling period resulted in delayed scaffold degradation, the 
deposition of disorganized connective tissue, and a lack of cellular infiltration within the ECM 
remodeling site [44]. These studies suggest that the reconstruction of ECM scaffolds into 
functional tissue is dependent upon a combination of temporally associated events, including 
timely scaffold degradation, cellular infiltration, and early exposure to site-appropriate 
mechanical loading. 
1.1.5 Summary 
Scaffold materials composed of intact ECM provide structural and biofunctional support to 
hematopoietic cells, fibroblasts, and other site appropriate cell types. ECM-based bioscaffolds 
retain the essential structural and functional molecules of their tissue of origin when 
decellularization is conducted by appropriate and effective methods. The beneficial biologic 
effects of ECM scaffold degradation and the associated loss of scaffold mechanical strength 
would suggest that a balance of these seemingly mutually exclusive events is necessary to realize 
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functional tissue reconstruction. The relationship between the host cellular response during the 
early stages of remodeling and the mechanical properties of the completely remodeled tissue is 
not fully understood. A goal of this dissertation is to investigate the associated between the early 
host mononuclear cell response after ECM scaffold placement and the functionality of remodeled 
tissue in an established rat model of musculoskeletal repair [36, 42].     
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2.0  HOST RESPONSE TO SCAFFOLD MATERIALS 
The classic paradigm of mammalian inflammation associates neutrophils with an active, acute, or 
persistent host inflammatory response and associates mononuclear cells with a subacute to 
chronic type of inflammatory response. The host response may further develop into a foreign 
body reaction by surface-adherent macrophages that fuse together to form multinucleate giant 
cells until the foreign body is degraded or surrounded by a fibrous capsule. However, the 
traditional model of the inflammatory response to biomaterials does not adequately describe the 
temporal observations of ECM scaffold remodeling. 
2.1 ROLE OF MACROPHAGES IN THE HOST RESPONSE 
2.1.1 Historical Perspective 
Mononuclear phagocytes (monocytes and macrophages) are found in most tissues of the body 
and are vital participants in the innate and acquired immune system. Circulating monocytes are 
the precursors to tissue macrophages, and are borne out of the bone marrow from a common 
myeloid progenitor. Upon release into the peripheral blood, monocytes circulate for several 
minutes to days before entering the tissues [101]. Monocytes are capable of differentiating into 
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morphologically and functionally heterogeneous effector cells, including resident tissue 
macrophages and inflammatory macrophages.  
Resident tissue macrophages perform specified functions that are required for different 
anatomical locations. A few examples include: alveolar macrophages in the lung, which are 
responsible for local defense against pathogenic and particulate matter  [102, 103]; Langerhans 
cells that populate the epidermis [103]; osteoclasts that remodel bone [103]; splenic macrophages 
and Kupffer cells in the liver, which foster the clearance of blood-borne pathogens [103]; and 
intestinal macrophages, which reside in the lamina propria of the small intestine and are 
characterized by high phagocytic and bactericidal activity, low production of co-stimulatory 
cytokines, and a lack of innate response expression, including the primary receptor for LPS, 
CD14 [85, 86].   
During the inflammatory response, blood monocytes are recruited to the wounded tissue 
by adhering to vessel endothelium and following local haptotactic and chemotactic gradients 
before differentiating into macrophages [102]. Macrophages, both resident and newly recruited, 
are the major producer of chemokines in wounded tissue, and are likely instrumental in the 
subsequent recruitment of additional macrophages.  
Conventional knowledge suggests that mononuclear macrophages follow neutrophils into 
a site of inflammation over time, phagocytose cellular debris and foreign material, and finally 
exit from the site of inflammation. The prolonged presence of a large population of mononuclear 
macrophages at the site of tissue repair is usually indicative of, and routinely diagnosed as, 
chronic inflammation with granulation tissue formation, with likely downstream outcomes such 
as necrosis, fibrosis with encapsulation, and/or some degree of scarring [70, 104]. Extensive 
research has shown that macrophages exhibit plasticity, i.e. the phenotype of macrophages can 
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change depending upon the local environment [78, 84, 103, 105-111]. Macrophages were once 
considered to be either classically activated or alternatively activated, but there is substantial 
heterogeneity in macrophage phenotype, due in part to the broad role that macrophages play in 
the inflammatory response and in the maintenance of tissue homeostasis. The thesis investigates 
the phenotypic profile of macrophages in the site of ECM scaffold remodeling in order to give a 
more accurate and complete description of the host response.   
2.1.2 Macrophage Phenotypes 
Mononuclear macrophages play an important role in modulating the inflammatory response to 
foreign materials, infection, and allergy through the synthesis and secretion of cytokines, 
chemokines, and growth factors [102]. Influenced by the local tissue and exposure to 
immunological microenvironment signals such as cytokines and microbial products, 
macrophages acquire distinctive morphological and functional characteristics. Macrophages 
perform critical functions in tissue repair, including collagen degradation and organization, 
promotion of angiogenesis, and other constructive processes [102], and act as effector cells in 
adaptive immune responses, such as in orchestrating helper T cells through the presentation of 
antigens [112]. 
Macrophage phenotype is classified according to gene expression, cell surface receptor 
expression, and secretion of cytokines. Macrophages that are induced to a classical activation 
profile by microbial products such as LPS or Th1 cytokines including interferon-gamma (IFN-γ) 
and tumor necrosis factor-alpha (TNF-α) are termed M1 macrophages [108, 112]. M1 
macrophages synthesize and release proinflammatory factors such as IL-1β, IL-6, IL-12, and 
TNF-α [113, 114], produce high concentrations of nitric oxide (NO) and reactive oxygen 
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intermediates (ROI), and produce type-1 chemokines such as CXCL-10, CXCL11, and CCL5. 
M1 macrophages are associated with microbicidal activity, tumor resistance, and cytotoxic tissue 
damage. By contrast, macrophages that are induced by IL4 or IL10 and promote a type-2 
response are called M2 macrophages. At least three distinct forms of M2 macrophages have been 
identified, and are categorized by the inducing agent: M2a macrophages, which are induced by 
IL-4 and IL-13, are classified as alternatively activated macrophages and drive type-2 responses; 
M2b macrophages, which are exposed to agonists of Toll-like receptors (TLRs) or IL-1R, are 
immunoregulatory and drive type-2 responses; and M2c macrophages, induced by IL-10 and 
glucocorticoid hormones, suppress immune responses and participate in matrix deposition and 
tissue remodeling (Figure 1) [108]. In general, M2 macrophages produce IL-10, transforming 
growth factor-beta (TGF-β), and type-2 chemokines such as CCL13 and CCL18 [108]. In 
particular, IL-10 is described as an immunosuppressive cytokine that functions to inhibit the 
production of proinflammatory cytokines and chemokines such as CXCL10, IL-1α/β IL-6, IL-12, 
and TNF, while amplifying the expression of their antagonists [115]. The expression of 
scavenger receptors such as the mannose receptor (CD206) and CD163 is strongly induced in 
macrophages by anti-inflammatory stimuli such as glucocorticoids and IL-10, and suppressed by 
proinflammatory mediators such as LPS, IFN-γ, and TNF-α [115-117]. M2 macrophages support 
parasite encapsulation and eradication, participate in the promotion of tumor growth and 
progression [118, 119], scavenge debris, and promote angiogenesis, tissue repair and 
homeostasis. M2 macrophages enhance fibrogenesis of mesenchymal cells (fibroblasts) by 
secreting soluble profibrogenic mediators such as TGF-β and platelet-derived growth factor 
(PDGF), while M1 macrophages inhibit fibrogenesis by releasing fibrolytic factors including 
matrix metalloproteinases (MMPs) and TNF-α [113]. The phenotype of macrophages involved in 
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the degradation and “processing” of ECM scaffold materials is likely dependent upon the local 
tissue and cellular environment, and has the potential to affect downstream characteristics of the 
remodeled scaffold materials. The body of work contained in this thesis examines the phenotypic 
profile of macrophages and determines its impact on the duration, magnitude, and overall 
outcome of the host response. 
 
 
Figure 1: Inducers, secreted products, and functional properties of macrophage populations polarized toward 
either an M1 phenotype or an M2 phenotypes. Reprinted from [108], with permission from Elsevier. 
 
The amino acid L-arginine plays an essential role in wound healing. Macrophages 
metabolize L-arginine in one of two distinct and competitive pathways (Figure 2). Macrophages 
from the M1 profile metabolize L-arginine through inducible nitric oxide synthase (iNOS; 
NOS2), which converts L-arginine to NO and L-citrulline, and results in a decrease of collagen 
synthesis by fibroblasts. M2 macrophages metabolize L-arginine via arginase, a critical enzyme 
that converts arginine to urea and L-ornithine [112]. L-ornithine is the substrate for two enzyme 
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pathways important in cell proliferation and collagen production during tissue repair, ornithine 
decarboxylase and ornithine aminotransferase, which increases concentrations of polyamines and 
L-proline, respectively [120, 121]. The reciprocal pathways of L-arginine metabolism may be a 
good predictor of how macrophages affect the outcome of inflammation. 
 
 
Figure 2: Schematic of the L-arginine pathway. Reproduced with permission from [122], the Biochemical 
Society [http://www.biochemsotrans.org] 
 
Caution is required when defining the M1/M2 classification scheme against rigid 
boundaries to what is, in reality, a broad spectrum that lies between the two extremes of 
polarization. Separating macrophages into only M1 or M2 macrophages risks an 
oversimplification of a continuum of diverse phenotypes that may be involved in ECM scaffold 
remodeling, since it is unlikely that macrophage phenotype is uniform throughout the remodeling 
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site. In addition, it is unclear whether M1 or M2 macrophages are terminally differentiated, have 
the ability to switch their phenotype, or become quiescent in response to micro environmental 
fluxuations in cytokine concentrations [109]. This dissertation will work within the confines of 
the current knowledge of the M1/M2 paradigm, but the complex milieu of ECM scaffold 
remodeling and the macrophage response is not fully understood. 
2.2 CONSTRUCTIVE REMODELING VERSUS FOREIGN BODY RESPONSE 
Constructive remodeling is best defined as a modification of the default wound healing 
mechanism away from scarring and toward regeneration and restoration of function. The cellular 
response to naturally derived ECM scaffold materials may not follow the conventional pattern of 
inflammation and can differ for each device, depending on the source of the material and the 
processing techniques which may include crosslinking with chemical agents. In a recent study 
that compared the host tissue response to five ECM products currently marketed for orthopedic 
applications, it was shown that an intense mononuclear macrophage response in the early post 
implantation period was a consistent finding (Appendix A) [42]. However, the long term 
remodeling outcome differed greatly for each product. The remodeled tissue showed chronic 
inflammation, fibrosis, scarring, and encapsulation (i.e., “foreign body response”) with some 
devices, and the formation of organized, site-appropriate tissue (i.e., “constructive remodeling”) 
for other devices. 
One hallmark of constructive remodeling is the presence of highly differentiated tissue 
structures (i.e., urothelium and smooth muscle bundles in the reconstruction of the urinary 
bladder after partial cystectomy and repair with ECM [27], and a continuous intact mucosal layer 
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of the esophagus and islands of skeletal muscle bundles after reinforcement of the cervical 
esophageal anastomoses with UBM [22]). Several mechanisms of ECM scaffold-mediated 
constructive remodeling have been attributed to site-appropriate mechanical loading from the 
onset of scaffold placement (Section 1.1.4), rapid and complete scaffold degradation (Section 
1.1.1), concurrent new host ECM deposition (1.1.2), and bioactive growth factors found within 
ECM scaffolds [47-49, 95, 96] or low molecular-weight peptides generated from the degradation 
products of ECM scaffolds (Section 1.1.1).  
2.2.1 Native (Non-crosslinked) ECM Scaffolds 
Although xenogeneic and allogeneic cellular antigens elicit an aggressive host inflammatory 
response or immune-mediated rejection, the components of ECM are conserved among 
mammalian species and are therefore well-tolerated by the recipient. The ideal processing 
techniques for ECM scaffolds decellularize the native tissue through mechanical, chemical, 
and/or enzymatic methods while minimally changing the biological properties and three 
dimensional ultrastructure [123]. Scaffold materials composed of intact ECM provide structural 
and biofunctional support to hematopoietic cells, fibroblasts, and other site-appropriate cell types 
[1, 4, 53, 90, 124, 125]. The remodeling characteristics of tissue repaired with native ECM 
scaffolds typically include such features as cellular infiltration and differentiation, scaffold 
degradation, new host ECM deposition, and the development of organized, site-specific tissue 
structures that resemble the native tissue in structure and function [43]. 
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2.2.1.1 Lymphocyte Response 
The immune response is a primary constituent of the host recognition to injury and implanted 
materials. Lymphocytes and helper T-cells (Th) in particular modulate the adaptive immune 
response through secreted cytokines [126]. One paradigm of lymphocyte biology classifies Th 
cells into two categories based on the secretion of specific cytokines related to macrophage 
activation. Th1 cells produce IFN-γ, TNF-α, and IL-12, and are thought to cause macrophage 
activation, differentiation of T-cells to a cytotoxic (CD8+) phenotype, and graft rejection. In 
contrast, Th2 cells produce IL-4, IL-5, IL-6 and IL-10, cytokines that inhibit macrophage 
activation [112, 127, 128]. SIS is the only ECM scaffold for which the Th1/Th2 response has 
been examined. In a study by Allman et al., mice were implanted subcutaneously with SIS, 
xenogeneic muscle tissue, or syngeneic muscle tissue to determine the host tissue and cellular 
response [58]. The xenogeneic tissue showed histological evidence of necrosis, granuloma 
formation, and encapsulation; these remodeling features are indicative of graft rejection. The 
syngeneic tissue and the SIS graft remodeled into organized tissue, and the inflammatory 
response was resolved, consistent with graft acceptance. In addition, SIS-ECM induced a Th2-
restricted immune response, as evidenced by suppression of IFN-γ and upregulation of IL-4. 
Palmer and colleagues investigated whether the presence of TGF-β in SIS influenced human Th 
cell activation and differentiation in vitro [129]. This study showed that SIS inhibited Th1 
expansion and cytokine production of IL-12 and IFN-γ in a TGF-β dependent manner and 
induced Th1 cell apoptosis. Furthermore, SIS also inhibited Th2 expansion, which was not 
rescued with exogenous TGF-β. These studies and others [10, 130, 131] may explain why there 
are no documented cases of immune-mediated rejection with SIS scaffolds.  
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2.2.1.2 Macrophage Response 
Mononuclear macrophages are commonly observed and are expected participants in the innate 
host inflammatory response to biomaterials, including those that are used as scaffolds for tissue 
reconstruction. A recently published study by our laboratory showed that the phenotype of 
mononuclear macrophages that participate in the host response to biologic scaffolds can differ 
markedly and that the method of material processing was an important variable [60]. In this 
study, the surgical sites in which the SIS device was placed showed an intense mononuclear cell 
response at 1, 2 and 4 weeks and infiltration of these cells between the individual layers of the 
multilaminate SIS device. These mononuclear cells were predominantly of an M2 phenotype 
(i.e., CD163+) at all timepoints (Figure 3A). By 16 weeks there was no evidence of the SIS-
ECM device and the surgical site was characterized by organized collagenous connective tissue, 
skeletal muscle tissue, and occasional CD163+ mononuclear cells (Figure 4A). This study 
suggests that the M2 macrophage response was associated with an organized, site-appropriate 
tissue-remodeling outcome and an absence of persistent inflammation. Furthermore, the presence 
of a cell population that is typically associated with cytotoxicity and inflammation (i.e., 
“macrophages”) was not necessarily predictive of the long term remodeling outcome. 
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 Figure 3: The macrophage polarization percentages for (A) SIS and (B) carbodiimide crosslinked SIS (CDI-
SIS) at 1 (white bars), 2 (light grey bars), 4 (dark grey bars), and 16 (black bars) weeks post-implantation in a 
rodent model of musculoskeletal repair. Mean ± standard error of the mean; *p < 0.001 and #p < 0.03. 
Reproduced from [60], with permission from Liebert Publishing. 
 
 21 
 Figure 4: Masson’s trichrome staining at 16 weeks post-surgery in a rodent model of musculoskeletal repair. 
(A) Photomicrograph of completely remodeled SIS device. Blood vessels, scattered skeletal muscle fibers, and 
organized collagen completely replaced the SIS device (100X). (B) Photomicrograph of carbodiimide 
crosslinked SIS device. A dense mononuclear cell response can be observed with the presence of 
multinucleate giant cells (arrows) and fibrosis around the scaffold material (400X). Reproduced from [60], 
with permission from Liebert Publishing. 
 
2.2.2 Chemically Crosslinked ECM Scaffolds  
The clinical utility of ECM scaffolds depends upon the ability of the scaffold material to provide 
adequate mechanical support to the injured or missing tissue being repaired. A common 
approach for increasing the strength of biologic scaffolds composed of ECM or components of 
ECM (e.g., purified type I collagen) has been the use of chemical crosslinking agents such as 
carbodiimide [13, 132-134], isocyanate [135] or glutaraldehyde [136-138]. While chemical 
crosslinking increases the mechanical strength of the scaffold, it also necessarily alters the 
kinetics of degradation and has a deleterious effect on the biologic activity of the degradation 
products. ECM scaffolds that are processed using chemical crosslinking methodologies [132, 
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139-141] are more likely to elicit a host response that is consistent with a synthetic material; that 
is, the response is characterized by chronic inflammation, minimal scaffold degradation, and 
fibrous encapsulation [142-146].  
2.2.2.1 Macrophage Response 
Crosslinking agents, such as carbodiimide (CDI), are often included in the processing of biologic 
materials to impart added strength and to slow the degradation rate (see Table 1). Collagen 
constitutes approximately 90% of the total protein content in many biologic scaffolds used in 
tissue engineering and regenerative medicine, including SIS. Collagen materials subjected to 
carbodiimide treatment show intra- and interhelical crosslinks of the tropocollagen molecules, 
which would logically change the surface architecture on a molecular level [147]. A recent study 
by Brown et al. showed that distinct structural changes in the arrangement of collagen fibers and 
minimal changes in the molecular composition of the surface of UBM scaffolds resulted from the 
use of carbodiimide as a crosslinking agent [148]. Macrophages are clearly affected by the 
surface topology and molecular organization of biomaterials, and the cell-surface interaction can 
change the quantity and identity of secreted proinflammatory cytokines and chemokines [149], 
the gene expression pattern [150], and downstream remodeling events [145, 146]. Chemical 
crosslinking can also lead to “frustrated phagocytosis” by macrophages [69], which may in turn 
affect their M1/M2 phenotype. In a recently published study by our laboratory, chemical 
crosslinking of the SIS scaffold with carbodiimide resulted in a switch from an M2 dominant 
profile to an M1 dominant profile (Figure 3B) and a change in the long-term (16 week) 
remodeling outcome from constructive remodeling to chronic inflammation (Figure 4B). 
Carbodiimide crosslinking was associated with an M1 response, long-term inflammation and the 
formation of multinucleate giant cells and scar tissue. 
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2.3 SUMMARY 
This dissertation expands the knowledge of macrophage phenotype outlined in Section 2.1.2 to 
include ECM scaffold remodeling as a way to develop a better understanding of constructive 
remodeling. Although this work limits the test articles to a single form of biologic scaffold 
material (SIS), the principles may also be applied to all scaffold materials, including synthetic 
and biologic materials.  
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3.0  CENTRAL HYPOTHESIS AND SPECIFIC AIMS 
The goal of this dissertation is to examine the phenotypic profile and contribution of 
macrophages to ECM remodeling in an animal model of musculoskeletal tissue reconstruction. 
The central hypothesis of this dissertation is that the phenotype of macrophages during the early 
stages of the remodeling process will predict downstream structural and functional properties of 
SIS remodeled tissue. Because of its extensive characterization and excellent remodeling 
properties in many soft tissue applications, SIS represents the prototype for naturally derived 
scaffold materials for studying the host response to bioactive scaffold materials and will be used 
for the proposed studies; however, the learned principles will likely be relevant for most, if not 
all, ECM-based bioscaffolds.   
 
Specific Aim 1.  To determine the phenotype of macrophages following contact with a 
biologic scaffold composed of small intestinal submucosa (SIS). Monocytes are active and 
important participants in the inflammation cascade, and have the ability to differentiate toward a 
proinflammatory (M1) macrophage or tissue remodeling and immunoregulatory (M2) 
macrophage. The present study will evaluate the phenotype of macrophages that are cultured on 
the surfaces of SIS scaffolds that differ only in the presence or absence of chemical crosslinking. 
Evidence suggests that low oxygen tension found in areas of inflammation can affect the 
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macrophage phenotype. To mimic the wound healing environment, atmospheric (20% oxygen) 
and low oxygen (6% oxygen) tensions will be compared.   
The specific aim was based on the hypothesis that monocytes will differentiate toward 
macrophages that express an M2-like phenotype when in direct contact with non-crosslinked 
SIS, while monocytes in direct contact with crosslinked SIS will differentiate toward an M1-like 
macrophage phenotype. 
 
Specific Aim 2: To determine the necessity of participation of macrophages for the 
degradation of SIS scaffolds. Macrophages efficiently respond to tissue injury and participate 
in the repair process. Phagocytosis is the hallmark of macrophage functionality. The constructive 
remodeling of SIS in past studies has always been associated with complete and relatively rapid 
degradation of the scaffold. In addition, the degradation products of ECM scaffolds have shown 
chemotactic and antimicrobial properties. By eliminating or significantly reducing the 
macrophage involvement in the host response, the benefits attributed to ECM degradation may 
not be realized.  
The hypothesis of the second specific aim is that depletion of macrophages will result in 
prolonged graft presence and a pro-inflammatory tissue cytokine profile at the site of scaffold 
placement. 
 
Specific Aim 3: To determine the histomorphology and functionality of SIS scaffolds when 
used for the reconstruction of musculoskeletal tissue in a rat model.  The default 
inflammatory response following muscle injury may initiate the process of scar tissue formation 
or promote reconstruction and repair. Previous studies have shown that specimens harvested 
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from one to sixteen weeks after implantation in a rodent model of musculoskeletal repair contain 
a macrophage response that may be useful in predicting the ultimate tissue functionality [60, 
151]. To date, the contractility of the repaired tissue in the abdominal wall repair model has not 
been investigated. The third aim will determine the in situ contractile properties and the 
histomorphologic characteristics of abdominal wall muscle tissue after repair with ECM 
scaffolds at the 6 month timepoint. In previous preclinical models, by 6 months the SIS grafts are 
completely remodeled with functioning, site specific tissue [8, 21, 24, 36, 40, 63]. 
 The hypothesis of the third specific aim is that abdominal wall muscle that is repaired 
with a noncrosslinked ECM scaffold will show contractile responses and histomorphologic 
characteristics comparable to the native muscle wall, while the crosslinked ECM scaffold will 
show little, if any, contractile forces and a histomorphologic profile that represents a foreign 
body reaction rather than a constructive remodeling response.  
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4.0  SPECIFIC AIM 1:  TO DETERMINE THE PHENOTYPE OF MACROPHAGES 
FOLLOWING CONTACT WITH A BIOLOGIC SCAFFOLD COMPOSED OF SMALL 
INTESTINAL SUBMUCOSA 
4.1 INTRODUCTION 
Previous studies have shown that ECM scaffolds derived from mammalian organs are excellent 
substrates for a variety of cell types, including the survival and outgrowth of primary neurons 
[152], the maintenance of human hepatocytes phenotype [87], the differentiation and functional 
characteristics of cardiomyocytes [153, 154], and the survival and proliferation of fibroblasts 
[125] and endothelial cells [3, 124]. The response of macrophages seeded onto ECM substrates 
may mimic the differentiation phenotype of macrophages involved in ECM scaffold remodeling 
in an in vivo setting. Therefore, macrophages seeded onto crosslinked and non-crosslinked ECM 
scaffolds may show altered expressions of various inflammatory-related markers in such a way 
that would be predictive of the constructive remodeling response observed in vivo. 
The objective of Specific Aim 1 was to characterize the protein and gene expression 
profile of human monocyte-derived macrophages when in direct contact with ECM scaffolds 
harvested from the small intestinal submucosa. The monocytes were selected by negative 
depletion to avoid the possible activation of the cell surface by bound antibodies. Cell culture 
was performed in atmospheric (20% oxygen) and low oxygen (6%) atmosphere. An enclosed cell 
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culture system (BioSpherix, Ltd., NY) was utilized so that all cell culture procedures for low 
oxygen experiments were performed and maintained in a controlled environment. 
4.2 MATERIALS AND METHODS 
4.2.1 Isolation and Preparation of Extracellular Matrix Scaffolds Derived from the Small 
Intestinal Submucosa (SIS) 
4.2.1.1 Preparation of SIS 
Established protocols for preparing the SIS scaffold material used in this study have been 
previously described [155] but are briefly reviewed below. The tissue from which the ECM 
bioscaffolds were prepared was harvested from the small intestine of market weight pigs (180 – 
270 kg). Immediately after euthanasia, the mesenteric tissues were removed. After rinsing, the 
tunica serosa, tunica muscularis externa, and the luminal portion of the tunica mucosa were 
mechanically removed. The tunica submucosa and the basilar portion of the tunica mucosa 
including the muscularis mucosa and the stratum compactum of the lamina propria were left 
intact, and these layers represented SIS. The SIS material was placed in a solution of 0.1% (v/v) 
peracetic acid (Sigma Chemical Co., St. Louis, MO), 4% (v/v) ethanol (Pharmco Products 
(Brookfield, CT), and 95.9% (v/v) sterile deionized water and shaken for 2 hours. The SIS 
material was then washed twice with phosphate buffered saline (PBS) at pH 7.4 and twice with 
deionized water for 15 minutes each to remove residual peracetic acid. The test article was then 
lyophilized and terminally sterilized with ethylene oxide at a dosage of 500 mg/L/h for 16 hours. 
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4.2.1.2 Preparation of Carbodiimide crosslinked SIS-ECM 
The SIS scaffolds designated as CDI-SIS were prepared by immersing the sheets of SIS in a 
solution of 10 mM carbodiimide (CDI) (Sigma) in 90% acetone/10% deionized water (v/v) for 
24 hours. To determine crosslinking efficacy, 6 samples each of SIS and CDI-SIS were digested 
in 27.3 U/mL bacterial collagenase type I (Sigma) for 72 hours at 37°C. The amino acids 
released in the supernatant were quantified in triplicate by the ninhydrin assay according to the 
manufacturer’s protocol. The CDI-SIS scaffolds were lyophilized and terminally sterilized by 
exposure to ethylene oxide at a dose of 500 mg/L/h for a 16 hour cycle. 
4.2.2 Human Monocyte Isolation and Culture 
Buffy coats prepared from six healthy human donors were obtained from the Central Blood Bank 
(Pittsburgh, PA). Peripheral blood mononuclear cells (PMBCs) were isolated using density 
gradient centrifugation (Lymphocyte Separation Media, Gibco, Carlsbad, CA; RPMI media, 
MediaTech, Inc., Manassas, VA). Monocytes were separated from PBMCs by immuno-magnetic 
depletion of T cells, natural killer cells, B cells, dendritic cells, and basophils using the 
Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Monocyte 
preparations were greater than 95% CD14+/CD115+, as indicated by flow cytometry.   
4.2.2.1 Differentiation of Monocytes into Macrophages 
Freshly isolated monocytes were cultured in RPMI media supplemented with 10% heat-
inactivated FBS (Gibco) and 1% penicillin/streptomycin (Gibco). Cultures were maintained at 
37°C in a humidified atmosphere containing 5% CO2 in either 20% oxygen/75% nitrogen or 6% 
oxygen/89% nitrogen environment. On day 3, cells were washed and fresh medium was added. 
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To stimulate the monocytes into M0 macrophages, macrophage-colony stimulating factor (M-
CSF) (100 ng/mL, R&D Systems, Minneapolis, MN) was included in the medium from day 0 to 
day 7. To stimulate the M0 macrophages into M1 macrophages, granulocyte macrophage (GM)-
CSF (1 ng/mL) (R&D Systems); IFN-γ (20 ng/mL) (R&D Systems); and LPS (10 ng/mL) (R&D 
Systems) were added to the medium at day 7. To stimulate the M0 macrophages into M2 
macrophages, IL-10 (50 ng/mL) (R&D Systems) or IL-4 (20 ng/mL) (R&D Systems) was 
included in the medium on day 7. The supernatants and macrophages were collected on day 8.   
4.2.2.2 Culture of Monocytes on SIS, CDI-SIS, or Tissue Culture Plastic (TCP) 
Freshly isolated monocytes were cultured in triplicate on the following substrates: tissue culture-
treated plastic (TCP), the luminal surface of SIS (i.e., stratum compactum), or the luminal 
surface of CDI-SIS. Stainless steel tissue culture rings with inner area of 1.5 cm2 were placed on 
the SIS and CDI-SIS scaffolds. Pressure was applied to create a seal and to hold the sheets of 
ECM on the bottom of the well. The scaffolds were incubated in 1 mL of XVIVO-15 media 
(BioWhittaker, Lonza, Walkersville, MD) supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin at 37°C and 5% CO2 for at least 4 hours prior to cell seeding, at which 
point the media was replaced just before adding the cells. The cells were seeded within the tissue 
culture rings at a density of 0.4 x 106 cells/cm2. After 8 hours the tissue culture rings were 
removed. The cells were grown on the substrates for 18 hours, 72 hours, or 168 hours at 37°C 
and 5% CO2, in 20% or 6% oxygen atmospheres. Eighteen hours prior to collecting the 
supernatant and harvesting the samples, the cell-seeded scaffolds were placed in a new well and 
fresh XVIVO-15 serum-free media was added (Figure 5).         
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 Figure 5: Schematic of culture conditions. 
4.2.3 Scanning Electron Microscopy 
Samples were fixed overnight at 4°C with 2.5% glutaraldehyde (TAAB Laboratories Ltd., 
Aldermaston, Berkshire, UK) in PBS. After 3 PBS washes, the tissues were immersed in 1% 
osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA) in PBS, dehydrated through a 
graded series of ethanol washes, from 30% - 100%, and then critical point dried by soaking the 
samples in hexamethyldisazane (Ted Pella Inc., Redding, CA) for 15 minutes. The samples were 
allowed to air dry, then immediately attached to aluminum SEM specimen mounting stubs 
(Electron Microscopy Sciences) and sputter coated with a 7-nm layer of gold-palladium 
(Cressington 108 Sputter Coater, Cressington Scientific Instruments, Cranberry, PA). Following 
processing, the samples were visualized using a JEM 6335F SEM (JEOL, Peabody, MA).  
4.2.4 mRNA Isolation and Quantitative Real Time RT-PCR Analysis 
Total RNA was isolated and purified using the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. RNA concentration and purity was determined 
by Nanodrop ND-1000 Spectrophotometer. RNA was stored at -20°C until further use. cDNA 
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was synthesized from 100 ng of total RNA in a volume of 20 μL using a Superscript RT III kit 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
Quantitative real time RT-PCR was performed using primers specific for genes known to 
be strong indicators of either an M1 (nitric oxide synthase 2 [NOS2], CXCL11, CXCL10 and 
CCR7) or M2 (arginase type 1 [ARG1], CCL13, CCL18, and mannose receptor C type 1 
[MRC1]) type macrophage response [122, 156] (Table 2). Primers were either custom designed 
using Beacon Designer 7.2 primer design software (PREMIER Biosoft International, Palo Alto, 
CA) and purchased from Operon Biotechnologies (Huntsville, AL) or predesigned primers were 
purchased from Real Time Primers (Elkins Park, PA). Primers for the housekeeping gene 
ribosomal protein L13A (RPL13A) were purchased as part of a housekeeping gene primer kit 
(Human Housekeeping Gene Primer Set, Real Time Primers), and was used to normalize 
reactions. One μL of cDNA was mixed with the appropriate primers and 2X SYBR Green 
Master Mix in a total volume of 25 μL. All reactions were performed in triplicate and were 
monitored using an iQ5 Real-Time Detection System (BioRad, Hercules, CA).  
Relative expression of each gene was calculated using the comparative Ct method [157, 
158]. The value of the threshold cycle (Ct) for the gene of interest was subtracted from the value 
of the threshold cycle for the housekeeping gene for each sample (ΔCt, sample) and for the 
freshly isolated monocytes of the respective donor (ΔCt, monocyte). For samples that did not 
reached threshold by the 40th cycle, the analytical value of the threshold cycle was designated as 
40. Relative expression to the donor-specific monocyte population was then calculated as 2(ΔΔCt), 
where  
ΔΔCt = (ΔCt, sample) - (ΔCt, monocyte). 
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Table 2: Sequences of Human-Specific Primer Sets Used in Real Time Analysis 
 
 
4.2.5 Measurement of DNA Content 
Total DNA was isolated using the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. Total DNA was quantified using the commercially 
available Quant-iT PicoGreen dsDNA Kit (Invitrogen-Molecular Probes, Eugene, OR) according 
to the manufacturer’s instructions. Each sample was measured in triplicate. 
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4.2.6 Protein Analysis of Supernatant 
The supernatants from the macrophage cultures were cleared through centrifugation, snap frozen 
in liquid nitrogen and stored at -80°C. SearchLight® Biomarker Testing Service (Aushon 
Biosystems, Billerica, MA) was utilized to determine the concentration of MMP9, CXCL10, 
CCL13, and CCL18 in the supernatant. SearchLight Array Technology uses a multiplexing 
sandwich-ELISA system based on chemiluminescent detection of analytes (information from 
www.aushon.com). The concentrations of each protein for SIS in media, CDI-SIS in media, and 
media only were subtracted from the concentrations detected for each sample. The protein 
amounts were then normalized to DNA content of each sample. 
4.2.7 Nitric Oxide Analysis of Supernatant 
The supernatants from macrophage cultures from two donors were prepared as described in 
Section 4.2.6. The concentration of nitric oxide (NO) was determined using the Griess Reagent 
(Sigma) according to the manufacturer’s instructions. Each sample was measured in triplicate. 
4.2.8 Statistical Methods 
All values are presented as mean ± standard error. For the mRNA expression and MMP9 protein 
concentration, a generalized linear model was used to determine statistical significance of the 
factors scaffold (SIS, CDI-SIS, and TCP), time (18, 72, and 168 hours), and oxygen 
concentration (6% and 20%), and the interaction between these factors. The data were 
transformed using natural log for the statistical analysis. Results were transformed back to the 
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original scale for presentation. The post-hoc Tukey’s (HSD) procedure was used to determine 
which pairs of levels of factors were significantly different when a main effect was statistically 
significant. For the CXCL10, CCL13, and CCL18 protein concentration data, the Kruskal-Wallis 
model was used to determine statistical significance, followed by the post-hoc Mann-Whitney 
procedure. Statistical analysis was performed using SAS 7.2 software. A p value of < 0.05 was 
considered statistically significant. 
4.3 RESULTS 
4.3.1 Crosslinking Efficacy 
The ninhydrin assay showed a greater concentration of free amino acids in the supernatants from 
SIS compared to CDI-SIS (547.1 ± 99.2 vs. 16.6 ± 7.4 μM/mg, p < 0.01), confirming that the 
CDI-SIS scaffolds were more resistant to collagenase degradation than the SIS scaffolds. 
4.3.2 Macrophage Morphology on Substrates 
For the M1-induced macrophages, several cells showed a flattened, ‘fried egg’ morphology, 
while the remaining cells showed a spindle-shaped morphology. The M2-induced macrophages 
remained mostly spherical, and the cell membrane showed a rippled appearance (Figure 6). 
Macrophages attached to the surfaces of SIS and CDI-SIS by 18 hours, and by 72 and 168 hours 
macrophages were concentrated in areas of topographical complexity. The macrophages in 
contact with SIS showed a rounded morphology at 72 hours, and by 168 hours the macrophages 
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coated the surface of the fibers (Figure 7). The macrophages in contact with CDI-SIS at 168 
hours showed a mixed morphologic appearance of rounded cells and flattened cells in areas that 
showed a raised surface (Figure 8). The macrophages cultured with complete media only showed 
a mixture of rounded, spindled cells and flattened cells at 72 hours, and by 168 hours the 
majority of macrophages showed a flattened morphology. There were no obvious differences in 
the morphology of the macrophages when comparing the oxygen concentrations. 
 
 
Figure 6: Comparison of morphologic appearance of M1 and M2-differentiated macrophages at 168 hours in 
20% and 6% oxygen concentrations. 
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 Figure 7: Comparison of morphologic appearance of macrophages on the luminal surface of SIS at 18, 72, 
and 168 hours in 20% and 6% oxygen concentrations. 
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 Figure 8: Comparison of morphologic appearance of macrophages on the luminal surface of CDI-SIS at 18, 
72, and 168 hours in 20% and 6% oxygen concentrations. 
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 Figure 9: Comparison of morphologic appearance of macrophages on glass coverslips in complete media only 
at 18, 72, and 168 hours in 20% and 6% oxygen concentrations. 
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4.3.3 Findings of mRNA Analysis  
4.3.3.1 NOS2 and CXCL11 mRNA Expression 
M1 macrophages were the only cells that showed expression of CXCL11. No macrophages 
showed expression of NOS2.  
4.3.3.2 Donor-specific mRNA Expression of Monocytes 
The baseline ΔCt values were determined for each donor (Figure 10). There were marked donor-
specific differences for CXCL10, CCR7 and CCL13.  
 
 
Figure 10: Baseline threshold cycle for each gene was subtracted from the threshold cycle for the 
housekeeping gene (ΔCt) from each donor of the isolate monocytes (Mono-#). 
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4.3.3.3 mRNA Expression for M0, M1, and M2-induced Macrophages 
The mRNA expression for the M1 (CXCL10 and CCR7) and M2 (CCL13, CCL18, and MRC1) 
markers used in the study was determined for M0, M1, and M2 macrophages (Figure 11). 
Compared to M2 macrophages, M1 macrophages showed higher expression of CXCL10 and 
CCR7, with the exception of M2 macrophages induced by IL-10 and cultured in 6% oxygen, and 
lower expression of CCL13, CCL18, and MRC1. CXCL10 showed an increased ratio toward the 
M1 phenotype, and CCR7 and CCL18 showed an increased ratio toward the M2 phenotype in 
20% oxygen compared to 6% oxygen (Table 3). CCL13 and MRC1 did not show appreciable 
differences in expression with respect to oxygen tension. 
 
 
Figure 11: mRNA expression for M0, M1, and M2-induced macrophages cultured in 20% and 6% oxygen. 
 
 
 
 42 
Table 3: Genes differentially expressed in M1 vs. M2 macrophages. 
 
 
4.3.3.4 Effect of Substrate and Oxygen Tension on CXCL10 mRNA Expression 
The statistically significant effects were for scaffold (P<0.003) and time (P<0.0001). Further 
analysis indicated that expression was higher for macrophages cultured on TCP compared to SIS 
and CDI-SIS, and expression was highest at 18 hours compared to 72 and 168 hours (Figure 12). 
No statistically significant effects were found for oxygen concentration. 
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 Figure 12: CXCL10 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen.  
 
4.3.3.5 Effect of Substrate and Oxygen Tension on CCR7 mRNA Expression 
The statistically significant effects were for scaffold (P<0.0002) and time (P<0.0001). Further 
analysis indicated that macrophages cultured on CDI-SIS showed higher expression compared to 
macrophages cultured on SIS and TCP, and expression was highest at 18 hours and lowest at 168 
hour (Figure 13). No statistically significant effects were found for oxygen concentration. 
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 Figure 13: CCR7 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between timepoints within a 
scaffold group. 
 
4.3.3.6 Effect of Substrate and Oxygen Tension on ARG1 mRNA Expression 
The statistically significant effect was for time (P<0.0001). Further analysis indicated that 
expression was lowest at 168 hours compared to 18 and 72 hours for all substrates (Figure 14). 
No statistically significant effects were found for scaffold or oxygen concentration. 
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 Figure 14: ARG1 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between timepoints within a 
substrate group. 
 
4.3.3.7 Effect of Substrate and Oxygen Tension on CCL13 mRNA Expression 
The statistically significant effects were for scaffold (P<0.011), time (P<0.0001), and scaffold by 
time interaction (P<0.006). Further analysis indicated that macrophages cultured on SIS and 
CDI-SIS showed higher expression compared to TCP, and expression was greatest at 18 hours 
compared to 72 and 168 hours (Figure 15). No statistically significant effects were found for 
oxygen concentration. 
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 Figure 15: CCL13 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between timepoints within a 
substrate group, and ‡ indicates statistical significance between substrate groups within a timepoint. 
 
4.3.3.8 Effect of Substrate and Oxygen Tension on CCL18 mRNA Expression 
The statistically significant effects were for scaffold (P<0.03), time (P<0.0001), oxygen 
concentration (P<0.02), oxygen concentration by time (P<0.03), and scaffold by time interaction 
(P<0.0007). Further analysis indicated that macrophages cultured on SIS showed higher 
expression compared to macrophages cultured on CDI-SIS, and the 18 hour timepoint was 
significant compared to 72 and 168 hours (Figure 16). 
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 Figure 16: CCL18 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between timepoints within a 
substrate group. 
 
4.3.3.9 Effect of Substrate and Oxygen Tension on MRC1 mRNA Expression 
The statistically significant effects were for scaffold (P<0.0005) and oxygen concentration by 
time interaction (P<0.05). Further analysis indicated that macrophages cultured on TCP showed 
significance compared to macrophages cultured on SIS and CDI-SIS (Figure 17). No statistically 
significant effects were found for time. 
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 Figure 17: MRC1 mRNA expression in macrophages cultured on SIS, CDI-SIS, and TCP at 18, 72, and 168 
hours in 20% and 6% oxygen. 
 
4.3.3.10 Summary of mRNA Findings 
The M1 markers CXCL10 and CCR7 showed a higher expression for macrophages cultured on 
CDI-SIS and TCP compared to SIS. These findings are comparable to the expression levels of 
M1 and M2-induced macrophages (Section 4.3.3.3). The M2 marker ARG1 did not show 
significance with respect to substrate or oxygen tension. The M2 markers CCL13 and CCL18 
showed a higher mRNA expression for macrophages cultured on SIS compared to macrophages 
cultured on TCP. The expression of CCL13 and CCL18 was not affected by oxygen tension for 
the M1 and M2-induced macrophages nor for the macrophages cultured on the test substrates. 
The M2 marker MRC1 showed a higher mRNA expression for macrophages cultured on SIS and 
CDI-SIS, irrespective of oxygen concentration. These findings are comparable to mRNA 
expression in M1 and M2-induced macrophages. In general, these results show that macrophages 
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express an M2-like phenotype when in cultured on SIS, while macrophages cultured on CDI-SIS 
or TCP express a mixed M1/M2-like phenotype. 
4.3.4 Findings of Protein Analysis 
4.3.4.1 Protein Concentration Findings for M0, M1, and M2-induced Macrophages 
The protein concentrations for MMP9 and the M1 (CXCL10) and M2 (CCL13 and CCL18) 
markers used in the study were determined for M0, M1, and M2 macrophages (Figure 18). 
MMP9 was expressed in equal amounts for all induced macrophages irrespective of oxygen 
tension. M1 macrophages showed a higher expression of CXCL10 and a lower expression of 
CCL13 and CCL18 compared to M2 macrophages. Comparing oxygen tension, the lower oxygen 
tension showed a trend toward a more polarized expression of M1 and M2 markers (Table 4). 
 
 
Figure 18: Protein levels in supernatants from M0, M1, and M2-induced macrophages at 168 hours in 20% 
and 6% oxygen. 
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Table 4: Proteins differentially expressed in M1 vs. M2 macrophages. 
 
 
4.3.4.2 Effect of Substrate and Oxygen Tension on MMP9 Protein Concentration 
The statistically significant effects were for scaffold (P<0.0005), time (P<0.0001), and scaffold 
by time interaction (P<0.02). Further analysis indicated that macrophages cultured on SIS 
showed significance compared to macrophages cultured on CDI-SIS and TCP, and protein 
concentration was highest at 168 hours and lowest at 18 hours (Figure 19). No statistically 
significant effects were found for oxygen concentration. 
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 Figure 19: Concentration of MMP9 in supernatants from macrophages cultured on SIS, CDI-SIS, and TCP 
at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group. 
 
4.3.4.3 Effect of Substrate and Oxygen Tension on CXCL10 Protein Concentration 
Macrophages cultured on SIS showed the lowest concentration of CXCL10 at 18 hours in 6% 
oxygen, and macrophages cultured on CDI-SIS showed the lowest concentration at 168 hours in 
20% oxygen (Figure 20). Macrophages cultured on TCP showed the highest concentration at 18 
hours in 20% oxygen, and 72 hours in 6% oxygen. No statistically significant effects were found 
for oxygen concentration. 
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 Figure 20: CXCL10 concentration in supernatants from macrophages cultured on SIS, CDI-SIS, and TCP at 
18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between timepoints 
within a substrate group, and ‡ indicates statistical significance between substrate groups within a timepoint. 
 
4.3.4.4 Effect of Substrate and Oxygen Tension on CCL13 Protein Concentration 
For most substrates, CCL13 concentration increased with time. Macrophages cultured on SIS 
showed the highest expression at 72 hours compared to macrophages cultured on CDI-SIS and 
TCP, while macrophages cultured on CDI-SIS showed the lowest expression at 72 and 168 hours 
compared to SIS and TCP (Figure 21). No statistically significant effects were found for oxygen 
concentration. 
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 Figure 21: Concentration of CCL13 in supernatants from macrophages cultured on SIS, CDI-SIS, and TCP 
at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group, and ‡ indicates statistical significance between substrate groups within a 
timepoint. 
 
4.3.4.5 Effect of Substrate and Oxygen Tension on CCL18 Protein Concentration 
For all substrates the concentration of CCL18 increased with time. Macrophages cultured on 
CDI-SIS showed the lowest concentration of CCL18 compared to macrophages cultured on SIS 
and TCP (Figure 22). No statistically significant effects were found for oxygen concentration. 
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 Figure 22: Concentration of CCL18 in supernatants from macrophages cultured on SIS, CDI-SIS, and TCP 
at 18, 72, and 168 hours in 20% and 6% oxygen. * indicates statistical significance (p < 0.05) between 
timepoints within a substrate group, and ‡ indicates statistical significance between substrate groups within a 
timepoint. 
 
4.3.4.6 Summary of Protein Analysis 
The protein levels of MMP9 were higher for macrophages cultured on SIS and TCP compared to 
CDI-SIS. The M1 cytokine marker CXCL10 showed a higher protein concentration for 
macrophages cultured on TCP compared to SIS and CDI-SIS. These findings are comparable to 
the concentration levels of M1 and M2-induced macrophages (Section 4.3.4.1). The M2 markers 
CCL13 and CCL18 showed higher protein concentration in the supernatant from macrophages 
cultured on SIS compared to CDI-SIS. The concentration of CCL13 was not affected by oxygen 
tension for the M1 and M2-induced macrophages nor for the macrophages cultured on the test 
substrates. Contradicting the findings from the M1 and M2-induced macrophages, the 
concentration of CCL18 for macrophages cultured on the test substrates was not affected by the 
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oxygen tension. In general, these results show correlation with the gene expression profiles in 
Section 4.3.3, although most of the gene markers were elevated at the 18 hour timepoint while 
the protein levels were elevated at 168 hours. 
4.3.5 Findings of Nitric Oxide Concentration Analysis 
There was little to no detectable nitric oxide in the supernatants from the M1 or M2-induced 
macrophages or the macrophages cultured on SIS, CDI-SIS, or TCP. 
4.4 DISCUSSION 
The results of the present study support the hypothesis of Specific Aim 1, in that macrophages 
cultured on the luminal surface of SIS showed an M2-like phenotype, while macrophages 
cultured on the surfaces of CDI-SIS and TCP showed a mixed M1/M2-like phenotype. Of 
interest, macrophages cultured on substrates that showed higher mRNA expression for CXCL10 
and CCL18 also showed higher protein concentrations for the same marker, although expression 
of the mRNA markers peaked at 18 hours and protein concentrations peaked at 168 hours.  
It is common practice to compare the relative ratio of iNOS to ARG1 as a way to 
determine macrophage function and phenotype for murine and rodent macrophages in vitro and 
in vivo. However, species differences do exist, and the methods that are used to stimulate 
macrophages may have a significant impact on the results. A study by Chiang and colleagues 
showed that resident peritoneal cells (PECs) from C3H/HeN mice stimulated in vivo with i.p. 
injections of LPS or IFN-γ showed opposing expression of iNOS and arginase, while PECs that 
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were harvested prior to stimulating in culture with LPS showed almost no expression of iNOS 
but did show detectable levels of ARG1 expression [159]. Several studies by Pham et al. 
determined that primary human monocyte-derived macrophages do not readily produce NO in 
culture, and that protein kinase C-eta (PKC-η) is at least one requirement for the development of 
iNOS expression [160, 161]. In the present study iNOS expression was absent and no NO was 
detected in the supernatant from cultures of human monocyte-derived macrophages.  
A finding of the present study was that for most markers the macrophages cultured on the 
test substrates did not show an increased polarization toward either an M1 or M2 profile in a 
lower oxygen tension. Low oxygen tension is a crucial physiological signal in wound healing by 
altering gene expression and metabolic activity, and induces marked changes in the proliferation 
rate, migration, differentiation, and secretory activity of most cells, including tumor associated 
macrophages, osteoblasts, chondrocytes, and stem cells [93, 107]. Previous studies have shown 
that monocytes and macrophages cultured in hypoxia up-regulate the transcription factors 
hypoxia-inducible factor 1 and 2 (HIF), which in turn activates a broad array of markers for 
monocyte recruitment including endothelial cell adhesion molecules and proangiogenic factors 
VEGF and angiopoietin-2 [162]. Hypoxia is also known to inhibit macrophage migration, 
chemotaxis, and proliferation [163, 164]. Work by Csete et al. has shown that various stem cell 
populations including rat fetal-derived neural crest stem cells, adult murine skeletal satellite 
cells, and rat marrow-derived mesenchymal stem cells cultivated in lower oxygen tensions show 
enhanced proliferation, reduced apoptosis, and enhanced differentiation into lineage-specific 
phenotypes [165]. Studies in our laboratory have complemented Csete’s results by showing that 
murine blastema (MRL-B) cells and human perivascular stem cells (MG-71) increased rate of 
proliferation and retained chemotactic and mitogenic properties to ECM digests when cultured in 
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low oxygen compared to atmospheric oxygen (data not published). The migration, chemotactic, 
or proliferative capacities of the monocyte-derived macrophages to SIS or CDI-SIS were outside 
the scope of the present study, but such an endeavor would be worthy of pursuit.  
Although the present study does not demonstrate a direct link between macrophages 
cultured on ECM substrates and in vivo remodeling, the findings in the present study coupled 
with the in vivo macrophage response observed in previous studies [60, 151] support the concept 
that the macrophage phenotype during ECM scaffold remodeling may contribute to the long-
term outcome. 
4.5 FUTURE STUDIES 
Future investigations may develop a macrophage-mediated protocol for producing ECM digest 
products, which may be a more physiologic method than digestion protocols that use acid/heat or 
pepsin. Experiments would utilize the Boyden chamber assay to study the chemotactic properties 
of these digests for progenitor cell lines such as MRL blastema cells or mesenchymal stem cells.  
Another prospective study may investigate the specificity of ECM scaffolds to the 
resident tissue macrophages that normally resided in the organ of origin. It would be interesting 
to show whether monocytes-derived macrophages adopt a profile that is more similar to the 
resident tissue macrophage rather than inflammatory macrophage phenotype. Such substrates/ 
macrophage combinations may include Kupffer macrophages cultured on liver-derived ECM or 
intestinal macrophages cultured on SIS. 
Further investigation is also warranted to understand the phenotypic changes that occur 
when macrophages are exposed to mechanical loading. Applying a stretching protocol to 
 58 
macrophages in direct contact with ECM scaffolds may alter the gene expression profile of 
markers important for remodeling, such as MMPs, collagen production, and angiogenic growth 
factors.  
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5.0  SPECIFIC AIM 2: TO DETERMINE THE NECESSITY OF PARTICIPATION 
OF MACROPHAGES FOR THE DEGRADATION OF SIS-ECM SCAFFOLDS 
It is intuitive and logical that phagocytic cells such as macrophages play an important role in 
ECM scaffold degradation but definitive studies to address the issue have not been reported. The 
concept of ECM scaffold degradation as a critical determinant of constructive tissue remodeling 
becomes even more clinically relevant when considering the widespread use of commercially 
available ECM materials that have been subjected to chemical and physical methods designed 
specifically to prevent scaffold degradation and increase the mechanical strength of the materials 
[132]. A recent study that compare several commercially available ECM scaffold materials has 
shown that the methods used to process these scaffolds, especially chemical methods to create 
molecular crosslinks, have marked effects upon host macrophage phenotype surrounding the 
ECM scaffold and downstream remodeling events (see sections 2.2.1.2 and 2.2.2.1) [60]. 
 The objective of Specific Aim 2 was to determine the contribution of mononuclear 
macrophages to the degradation and early remodeling events that follow the implantation of 
ECM scaffolds for the purpose of tissue reconstruction. This objective was accomplished by 
evaluating the degradation and remodeling response of native and chemically crosslinked ECM 
in a rat model of abdominal wall repair with and without macrophage depletion. Both of the 
scaffolds tested in the study mimic products that are used clinically for augmentation of the 
rotator cuff [166]. Macrophage depletion was accomplished by administration of clodronate-
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containing liposomes that are subjected to phagocytosis by circulating monocytes. Apoptosis of 
monocytes occurs when intracellular clodronate reaches a threshold concentration [167-169]. 
Liposomes do not cross the vascular-endothelial barrier, so only circulating monocytes are 
affected. Stated differently, resident tissue macrophages remain unaffected by the clodronate 
treatment.   
5.1 MATERIALS AND METHODS 
5.1.1 Overview of Experimental Design 
Forty-eight adult rats were randomly divided into three equal groups (n = 16 for each group). A 
1.5 cm2 partial thickness defect was created in the ventro-lateral abdominal wall of each animal. 
The defect was replaced with one of three different materials: a 10 layer configuration of an 
ECM biologic scaffold composed of porcine-derived SIS radiolabeled with 14C (14C-SIS); a 10 
layer configuration of the same form of porcine-derived 14C-SIS test article except for the use of 
carbodiimide as a crosslinking agent (14C-X-SIS); or autologous body wall tissue. Each group 
was divided into 3 sub-groups.  Subgroup No.1 was administered clodronate-containing 
liposomes twice weekly (n=8). Subgroup No.2 was administered PBS-containing liposomes 
twice weekly (n=4). Subgroup No.3 was administered twice weekly treatments with saline 
vehicle (n=4). One half of the animals in each subgroup were sacrificed one week after surgery. 
The remaining animals were sacrificed two weeks following surgery. The implanted scaffold 
materials plus surrounding host native tissue were explanted and examined by 1) histologic and 
immunohistochemical methods to determine the participation of blood derived macrophages in 
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the host response and to characterize the scaffold remodeling response; 2) liquid scintillation 
counting for 14C content to quantify the extent of SIS scaffold degradation; and 3) real time RT-
PCR to determine the effects of macrophage depletion on the M1/M2 profile of the remodeling 
site.  
5.1.2 Test Article Preparation  
5.1.2.1 Preparation of 14C-SIS  
SIS was manufactured from the small intestine of 26 week old pigs that received weekly 
injections of 10 µCi of 14C-labeled proline from 3 to 26 weeks of age [63, 64]. The injected 
proline (or as modified in vivo to form hydroxyproline) is integrally incorporated into collagen. 
Proline and hydroxyproline account for approximately 10% of the amino acids in collagen, and 
collagen accounts for 90% of the dry weight of SIS. This protocol of 14C-labeled proline 
administration results in a two to four-log increase in 14C content within porcine ECM and thus 
serves as a tool for quantification of labeled ECM at the site of interest (Figure 23) [63, 64]. 
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 Figure 23: Counts of 14C per minute per gram of labeled porcine tissues using liquid scintillation counting. 
The more metabolic tissues (aorta, liver, small intestine) tended to have higher levels of 14C at approximately 
3500 CPM/g. Reprinted from [64], with permission from Elsevier. 
 
The isolation of SIS from the small intestine has been previously described (4.2.1.1)  
[155], but is summarized briefly herein. Immediately following euthanasia, the small intestine 
was harvested and the mesenteric tissues were removed. After rinsing, the tunica serosa, tunica 
muscularis externa, and the luminal portion of the tunica mucosa including most of the lamina 
propria were mechanically removed. The remaining layers represented 14C-SIS, and consisted of 
the tunica submucosa and the basilar portion of the tunica mucosa including the muscularis 
mucosa and the stratum compactum of the lamina propria. The 14C-SIS material was disinfected 
and decellularized with 0.1% peracetic acid and rinsed in hypotonic saline. The amount of 14C 
incorporated in SIS was 3500 counts per minute (CPM) per gram, compared to a background 
level of 25 CPM [64].  
The 14C-SIS scaffolds were constructed by stacking 10 layers of the ECM and subjecting 
them to a vacuum of 710 to 740 mm Hg for 10 to 12 hours to remove the water and form a 
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tightly coupled multilaminate device.  Ethylene oxide was used for terminal sterilization (500 
mg/liter/hr for 16 hours). 
5.1.2.2 Preparation of Carbodiimide Crosslinked 14C-SIS 
The chemical crosslinking agent used was carbodiimide (CDI), which has been used widely used 
to crosslink commercially available ECM scaffolds [13, 133, 134].  The SIS scaffolds designated 
as 14C-X-SIS were prepared by immersing the multilaminate 14C-SIS scaffolds in a solution of 10 
mM CDI (Sigma, St. Louis, MO) in 90% acetone/10% deionized water (v/v) for 24 hours. To 
determine crosslinking efficacy, 8 samples each of 14C-SIS and 14C-X-SIS were digested in 
triplicate in 27.3 Units/mL bacterial collagenase Type I (Sigma) for 72 hours, and the amino 
acids released in the supernatant were quantified by the ninhydrin assay according to the 
manufacturer’s protocol. The 14C-X-SIS scaffolds were terminally sterilized by exposure to 
ethylene oxide at a dose of 500 mg per liter hour for a 16 hour cycle. 
5.1.3 Animal Care Compliance 
All procedures were performed in accordance with the National Institute of Health (NIH) 
guidelines for care and use of laboratory animals, and with approval of the Institutional Animal 
Care and Use Committee (IACUC) and Radiation Safety Office (RSO) at the University of 
Pittsburgh.   
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5.1.4 Experimental Animals and Husbandry 
Forty-eight adult male Sprague-Dawley rats weighing approximately 300 grams were purchased 
from Charles River Laboratory (Wilmington, MA). Each animal was housed individually in 
sterile microisolator cages. The rats were fed a diet of gamma-irradiated Purina rodent chow 
(LabDiet ProLab Isopro RMH 3000, PMI Nutrition International, St. Louis, MO) and sterile 
autoclaved water, and were housed individually in an environment maintained at 68° to 76°C for 
twenty four hours a day and with a light:dark cycle of 12:12 hours.   
5.1.5 Surgical Procedure 
An established rat model of abdominal wall repair was used to evaluate the host morphologic 
response to each implanted biomaterial [36]. This model includes muscle tissue, the presence of 
a variable and multidirectional load, and a clinically obvious failure outcome (i.e., hernia).   
 Each animal was anesthetized with Isoflurane (2% in oxygen) in an inhalation chamber. 
The surgical site was clipped, shaved and prepared for sterile surgery with a betadine scrub. 
Sterile technique was used at all times. A ventral midline abdominal incision was made and the 
skin and subcutaneous tissue were separated from the underlying muscle tissues on one side of 
the midline for a distance of approximately 4.0 cm. The incision in the ventral midline of the 
abdominal skin was retracted to expose the ventral lateral wall adjacent to the linea alba, 
including the musculotendinous junction of the abdominal wall musculature.    
A 1.5 cm x 1.5 cm partial thickness segment consisting of the oblique layers of the 
abdominal wall was excised leaving the underlying transversalus fascia and peritoneum intact 
(Figure 24). Uniformity of the defect size and shape was assured by using a fixed size and shape 
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device on each animal. The defect was then replaced with a size-matched graft of the 14C-SIS 
device, the 14C-X-SIS device, or the autologous abdominal wall tissue. One 4-0 Prolene suture 
was placed at each of the four corners of the test article to secure attachment to the adjacent 
abdominal wall and to demarcate the implant. Securing the test articles in this manner provided a 
mechanism by which the test article was subjected to the mechanical forces delivered by the 
adjacent native abdominal wall musculature, while avoiding the predominance of a host tissue 
reaction to the suture material rather than the test article. A subcuticular placement of 4-0 Vicryl 
was used to close the skin incision. Each animal was recovered from anesthesia on a heating pad 
and returned to its housing unit.    
Ketoprofen (5 mg per kg of body weight) was administered by subcutaneous injection the 
day of surgery and for two additional days. Baytril (20 mg) was given orally the day of surgery 
and for two additional days. The dietary habits, general health status, and the surgical site were 
monitored daily. Any animal showing signs of infection or uncontrollable pain was immediately 
euthanized and removed from the study. 
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 Figure 24: Schematic and histological depiction of the partial thickness abdominal wall defect model 
(Masson’s trichrome, 40X). 
 
5.1.6 In Vivo Macrophage Depletion 
Clodronate (dichloromethylene bisphosphate, Cl2MBP, Sigma Aldrich, St. Louis, MO) was 
encapsulated in multilamellar liposomes, as described [167, 170]. Clodronate was prepared at a 
concentration of 2.5 grams per 10 mL of PBS solution [170]. In the present study, clodronate 
liposomes were injected IV in the lateral tail vein to deplete monocytes from the peripheral 
blood. PBS-encapsulated liposomes labeled with the fluorochrome DiI [71] (Molecular Probes, 
Eugene, OR) or saline served as the control injections. The volume of each injection was 0.1 ml 
liposome solution or saline solution per 10 grams of body weight. Injections were given 2 days 
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and 2 hours prior to surgery. Subsequent injections were then given twice weekly until the 
predetermined time of sacrifice.  
5.1.7 Euthanasia and Specimen Harvest 
At the predetermined time of sacrifice, the animals were anesthetized with 5% isoflurane and 
euthanized by an intracardiac bolus injection of potassium chloride (KCl) to induce cardiac 
arrest. The surgical site was explanted with an equal amount of adjacent native abdominal wall 
tissue. The specimens were quartered and prepared by: 1) fixing in 10% neutral buffered 
formalin for histologic and immunohistochemical analysis; 2) frozen for immunofluorescent 
imaging studies (i.e., animals treated with DiI-labeled PBS liposomes); 3) frozen for 14C 
quantification (i.e., animals that received the 14C-SIS and 14C-X-SIS scaffolds); or 4) stored in 
RNAlater for RNA isolation. Liver and spleen specimens were also harvested and prepared for 
histology and immunoanalysis to monitor the efficacy of the macrophage depletion protocol. 
5.1.8 Quantification of Degradation 
The 14C radioactivity of the specimens from animals that received the 14C-SIS and 14C-X-SIS 
scaffolds was determined by liquid scintillation counting (LSC) using a LSI1800 B-counter 
(Beckman Coulter, Somerset, NJ). Approximately 80 mg of each specimen was incubated in 
Solvable (PerkinElmer, Waltham, MA) for 2-4 hours at 50-60 ºC until solubilized. Ten milliliters 
of scintillation fluid (Ultima Gold, PerkinElmer) was added to each sample, and quantification of 
14C was recorded as counts per minute (CPM). Background 14C activity was subtracted from the 
recorded activity and the CPM were determined for each scaffold. 
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5.1.9 Histology and Immunohistochemistry 
The specimens that were fixed in neutral buffered formalin were embedded in paraffin and serial 
sections of the embedded tissue specimens were cut at 6 µm intervals for hematoxylin and eosin 
(H&E) staining and immunohistochemical analysis. The sections were prepared for 
immunohistochemical staining by deparaffinization with xylene, and rehydration through a 
graded ethanol series. A heat-mediated antigen retrieval technique that included a 20 minute boil 
in 0.01M citrate buffer (Spectrum, New Brunswick, NJ), pH 6.0 was used. After cooling, two 
separate five-minute washes in TBS/Tween20, pH 7.4, followed by one wash in PBS were 
performed. 
5.1.9.1 Antibodies  
The primary antibodies used for immunohistochemical staining were mouse anti-rat CD68 
(Serotec, Raleigh, NC) at 1:50 dilution in PBS, mouse anti-rat CD163 (Serotec) at 1:50 dilution, 
and rabbit anti-CCR7 (Cell Applications, Inc., San Diego, CA) at 1:100 dilution. CCR7 is a 
surface marker indicative of an M1 phenotype, and CD163 is a surface marker representative of 
an M2 phenotype [60, 108, 151]. The secondary antibody used was biotinylated anti-mouse IgG 
(H+L) (Vector, Burlingham, CA) at 1:200 dilution for CD68 and CD163, and biotinylated anti-
rabbit IgG (H+L) (Vector) for CCR7.  Formalin fixed rat spleen served as the positive control 
tissue for all immunohistochemical procedures. 
5.1.9.2 Immunohistochemistry Procedure  
To prevent non-specific antibody binding, the slides were incubated for thirty minutes with 2% 
normal horse serum (Vector) at room temperature. The slides were incubated with 3% hydrogen 
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peroxide (Spectrum) in methanol for thirty minutes at room temperature to inhibit endogenous 
peroxidase activity. The slides were incubated with the secondary antibody for thirty minutes at 
room temperature, followed by horseradish peroxidase solution (Vector) for thirty minutes at 
37ºC. Diaminobenzidine (DAB) (Vector) was applied to detect positive staining cells and the 
slides were counterstained with hematoxylin.  
5.1.9.3 Quantitative Analysis of Macrophages 
Quantitative analysis of CD68+ cells was conducted independently by two investigators who 
were blinded to the identity of the tissue specimen. Cells immunopositive for CD68 were 
counted for each tissue specimen in ten microscope fields at 400X magnification at the host-
implant interface.  
5.1.9.4 Analysis of M1/M2 Ratio 
Quantitative analysis was conducted independently by two investigators who were blinded to the 
identity of the tissue specimen and to the antigen being positively identified in each specimen. 
Immunopositive cells were counted for each specimen in six matched microscope fields at 400X 
magnification. The percentage of cells expressing an M1 phenotype was calculated by dividing 
the number of CCR7+ cells by the number of CD68+ cells in each field. The percentage of cells 
expressing an M2 phenotype was determined by dividing the number of CD163+ cells by the 
number of CD68+ cells in each field. The mean value for the percentage of cells showing an M1 
and M2 phenotype was then calculated by obtaining the average of the six fields for each 
specimen at each timepoint. A comparison of M1 to M2 was then calculated for each specimen 
at each timepoint for each field. Values were plotted such that positive values were 
representative of the predominance of M1 cells among those cells that stained immunopositive 
 70 
for either M1 or M2 markers. Conversely, a negative value was representative of a predominance 
of M2 cells. Not all macrophages showed differentiation markers to an M1 or M2 state which 
accounted for the total number of M1 plus M2 macrophages not necessarily equaling the number 
of CD68+ cells [171].  
5.1.9.5 Immunofluorescence 
The frozen tissue sections from animals that received DiI-labeled PBS liposomes were analyzed 
by fluorescent microscopy to determine the colocalization of DiI-labeled cells with CD68 labeled 
cells, presumably macrophages that had phagocytosed liposomes. The primary antibody was 
mouse anti-rat CD68 (Clone ED1, Serotec) at 1:100 dilution in PBS. The secondary antibody 
used was Alexafluor 488-labeled goat anti-mouse IgG (H+L) (Invitrogen, Carlsbad, CA) at 1:250 
dilution. Frozen sections were fixed in ice cold acetone for 5 minutes. After air drying the tissue 
sections, two separate 5 minute washes in PBS, followed by three washes in PBS-0.1% Tween 
20 (Sigma) were conducted. The slides were incubated for 30 minutes with 2% normal goat 
serum (Vector), and incubated with the primary antibody for 60 minutes at room temperature. 
The slides were incubated with the secondary antibody for 30 minutes at room temperature, and 
dehydrated through a graded series of ethanol. The slides were coverslipped with an aqueous 
medium containing DAPI (Vector).   
5.1.10 Gene Expression Analysis 
5.1.10.1 RNA Isolation 
The section of the explanted tissues stored in RNAlater (Qiagen, Valencia, CA) was stored at 
4ºC until RNA isolation was performed. Total RNA was isolated from the specimens using TRI-
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Reagent (Molecular Research Center Inc., Cincinnati, OH) according to the manufacturer’s 
instructions. The isolated RNA was then purified using an RNeasy Mini Kit (Qiagen). cDNA 
was synthesized from 1 µg of total RNA in a total volume of 20 µL using a Superscript RT III kit 
(Invitrogen) according to the manufacturer’s instructions. 
5.1.10.2 Quantitative Real Time RT-PCR. 
Quantitative real time RT-PCR was performed using primers specific for genes known to be 
indicators of either a type I response (iNOS and IFN-γ) or a type II response (ARG-1 and IL-10) 
(Table 5). Primers were custom designed using Beacon Designer 7.2 primer design software 
(PREMIER Biosoft International, Palo Alto, CA). The housekeeping gene β glucurodinase 
(GUSB) was used to normalize reactions, and was purchased as part of a housekeeping gene 
primer kit (Rat Housekeeping Gene Primer Set, Real Time Primers, LLC, Elkins Park, PA). One 
µL of cDNA was mixed with the appropriate primers and 2X SYBR Green Master Mix (BioRad, 
Hercules, CA) in a total volume of 25 µL per reaction in triplicate. All reactions were monitored 
using an iQ5 Real-Time Detection System (BioRad). 
 
Table 5: Sequences of Rat-Specific Primer Sets Used in Real Time Analysis 
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5.1.10.3 Gene Expression 
Relative expression of the genes was calculated using the comparative Ct method [157, 158]. 
The value of the threshold cycle (Ct) for the gene of interest was subtracted from the value of the 
threshold cycle for the housekeeping gene for each sample (ΔCt, sample) and for native muscle 
(ΔCt, reference). Relative expression to the native muscle was then calculated as 2(ΔΔCt), where  
ΔΔCt = (ΔCt, sample) - (ΔCt, reference). 
Genes for the enzymes iNOS and ARG-1 use the same substrate, L-arginine (see section 
2.1.2). iNOS is required for nitric oxide production and is the predominate arginine usage 
pathway in M1 macrophages. ARG-1 is inhibitory for iNOS and is the predominate arginine 
usage pathway in M2 macrophages. The relative expression of iNOS and ARG-1 in each 
specimen was compared using the following equation:  
2(ΔΔCt, iNOS)   
2(ΔΔCt, ARG-1) 
  
Values were then plotted on a log scale such that values greater than 1.0 represented a 
predominance of the iNOS gene expression and values less than 1.0 represented a predominance 
of ARG-1 gene expression.  
5.1.11 Statistical Analysis  
The mean values for CD68+ cells for each group and subgroup was determined and the group 
values compared using one way analysis of variance (ANOVA). A mixed model ANOVA was 
used to analyze the immunohistochemical data. The factors were scaffold (autologous, 14C-SIS, 
and 14C-X-SIS), treatment (clodronate liposomes, PBS liposomes, and saline), time (one week 
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and two weeks), and area (6 different areas on each slide). A one way ANOVA was used to 
analyze the gene expression data. Results were considered significant for p < 0.05.  
5.2 RESULTS 
5.2.1 Crosslinking Efficacy 
The ninhydrin assay showed a greater concentration of amino acids in the supernatants from 14C-
SIS compared to 14C-X-SIS (523.5 ± 40.0 vs. 263.3 ± 74.9 µM/mg, P < 0.01), confirming that 
the 14C-X-SIS scaffolds were more resistant to collagenase degradation than the 14C-SIS 
scaffolds. 
5.2.2 Surgical and Post-operative Outcomes 
No complications occurred during the surgical procedures for any animal in this study. All 
animals assigned to the one week timepoint survived without complication. Five out of the 24 
animals with a survival timepoint of two weeks died prior to the scheduled date of sacrifice. All 
of the animals that died prematurely had been administered clodronate liposomes. None of the 
animals that were administered the PBS liposomes or saline vector died prematurely. This 
outcome was not specific to any particular scaffold group. Histopathologic analysis of lung, 
spleen, and liver tissue specimens from the animals that died prematurely showed widely 
disseminated foci of parenchymal necrosis associated with colonies of bacteria and an absence of 
inflammatory cells. These findings were consistent with overwhelming sepsis secondary to 
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clodronate-induced phagocyte depletion. The animals that died prematurely were replaced in the 
study, and these replacement animals survived until the study endpoint.  
5.2.3 Quantification of Degradation 
At 1 and 2 weeks, LSC counts per minute (CPM) of the 14C-SIS graft sites from clodronate-
treated animals showed higher levels of 14C when compared to graft sites from PBS liposome or 
saline treated animals (p < 0.05). At 2 weeks, CPM of PBS liposome-treated animals were less 
than the CPM from saline-treated animals (p < 0.05). CPM of 14C-X-SIS graft sites from 
clodronate liposome, PBS liposome, and saline treated animals were all similar at 1 and 2 weeks, 
and these 14C levels were also similar to the non-implanted scaffold (Table 6). 
 
Table 6: Quantification of 14C-SIS and 14C-X-SIS Scaffold Degradation, as Measured by LSC 
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5.2.4 Histopathologic Findings 
5.2.4.1 Autologous Tissue Graft 
The autologous tissue graft from animals treated with clodronate-containing liposomes showed 
mild coagulative necrosis of the muscle fibers that were part of the autologous graft tissue, and 
these fibers were surrounded by partially organized collagenous tissue. Widely scattered 
mononuclear cells and neutrophils were noted at both the 1 and 2 week time points. The animals 
that received the saline or PBS liposomes treatment showed that the autologous graft tissue was 
infiltrated with a dense population of mononuclear cells and a smaller number of neutrophils at 1 
and 2 weeks post-implantation. The muscle fiber bundles of the autologous graft tissue showed 
degeneration and necrosis at 1 week post surgery. By 2 weeks, the tissue specimens of saline-
treated animals showed that the tissue graft was almost totally replaced with collagenous tissue 
with remnants of degenerative or necrotic muscle remaining. The tissues from PBS-liposome 
treated animals showed remnants of skeletal muscle fibers dispersed within new host ECM and 
scattered accumulations of adipose tissue (Figure 25). 
5.2.4.2 14C-SIS Scaffold 
The animals treated with the clodronate liposomes showed a markedly reduced mononuclear cell 
response for both timepoints. At 1 week, the scaffold did not adhere to the surrounding host 
tissue at the time of sacrifice, and at 2 weeks the scaffold was characterized histologically by 
mononuclear cells in a loosely organized matrix. Neutrophils were present adjacent to the 
scaffold surface and were occasionally present between the individual layers of the delaminating 
scaffold.  
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The surgical sites in which the 14C-SIS device was placed in rats that received either 
PBS-liposomes or saline showed an abundant mononuclear cell response at 1 and 2 weeks. 
Animals treated with PBS-liposomes showed that most of the 14C-SIS scaffold was degraded by 
2 weeks, a finding that correlated with the 14C levels found at the graft site. The scaffold was 
replaced with new host ECM and was densely populated by mononuclear cells and blood 
vessels.  
For the saline treated animals, by 2 weeks the scaffold was delaminated and the 
individual layers at the edges of the scaffold were surrounded by new host ECM. Mononuclear 
cells were abundant and these cells surrounded and infiltrated the entire scaffold implantation 
area (Figure 25).  
5.2.4.3 14C-X-SIS Scaffold 
Specimens from animals treated with the clodronate liposomes showed almost complete absence 
of mononuclear cells and a dense population of neutrophils at the implantation site. The scaffold 
showed no evidence of delamination and appeared to be completely intact. At 1 and 2 weeks the 
scaffold was loosely attached to the surrounding host tissue.  
The animals that received saline or PBS liposomes showed a dense population of 
mononuclear cells and neutrophils around the 14C-X-SIS material at 1 and 2 weeks. These cells 
were present at the periphery of the scaffold material with little to no infiltration of cells into the 
scaffold itself. The layers of the scaffold remained essentially intact, and showed no morphologic 
evidence of degradation, a finding that was consistent with the LSC data (Figure 25).  
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 Figure 25: Representative images of autologous, 14C-SIS, and 14C-X-SIS scaffold implantation sites 2 weeks 
post-implantation. Graft sites from animals treated with clodronate liposomes showed almost no scaffold 
degradation. Graft sites from animals treated with PBS liposomes or saline show dense accumulations of 
mononuclear cells for all graft types and scaffold degradation for the autologous and 14C-SIS scaffolds. 
Arrows point to muscle cells that remained in the autologous tissue graft site. For the 14C-SIS and 14C-X-SIS 
scaffolds, asterisks (*) indicate the layers of the original multilaminate scaffolds that remain in the 
implantation site. Sections were stained with H&E. Scale bar = 100 μm. 
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5.2.5 Immunohistochemical Findings 
Macrophage depletion was noted in the spleen of all animals treated with clodronate liposomes at 
1 and 2 weeks post-implantation, confirming the effectiveness of the depletion procedure. For 
each graft type at 1 and 2 weeks, the surgical sites from the clodronate liposome-treated animals 
showed fewer macrophages (CD68+ cells) than graft sites from PBS liposome and saline-treated 
animals at both time points for all graft materials (p < 0.001) (Figure 26). Animals treated with 
the DiI-labeled PBS liposomes showed DiI-labeled cells that co-localized with CD68+ cells at 
the site of tissue remodeling, verifying that liposomes were engulfed by circulating mononuclear 
cells and that these circulating cells subsequently populated the remodeling site in animals not 
treated with clodronate (Figure 27). 
 
 
Figure 26: CD68+ cells per 400X field, 10 fields per graft site, examined at the host-implant interface. Data 
represent mean ± SD. *Significant compared with PBS liposome control (p < 0.001); #significant compared 
with saline control (p < 0.001). 
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 Figure 27: Immunofluorescent images of scaffold sites 2 weeks post-implantation from animals that received 
IV injections of DiI-labeled PBS liposomes. The distribution of DiI-labeled cells (red), CD68+ macrophages 
(Alexafluor 488, green), and cell nuclei (DAPI, blue) are shown in merged images. Scale bar = 100 μm. 
 
Representative images of the immunohistochemical staining for each M1/M2 marker at 
one week post-implantation are shown in Figure 28. A quantitative analysis of the phenotype of 
the macrophages present in the remodeling autologous tissue graft showed that the polarized 
macrophages (those expressing either CCR7 or CD163) were a mixed population of 
CCR7+/CD163+ macrophages for all treatment groups at one week and for the saline treatment 
group at two weeks, and a predominately M2 (CD163+) response for the clodronate and PBS 
liposome treatment groups at two weeks (Figure 29A). For the 14C-SIS scaffold, the 
macrophages expressed mostly an M2 phenotype (CD163+) for all treatment groups at one and 
two weeks post-implantation (Figure 29B). The macrophages present in the remodeling site of 
14C-X-SIS scaffold showed that at one and two weeks a mixed population of macrophages 
(CCR7+/CD163+) was present for all treatment groups (Figure 29C). 
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 Figure 28: Representative photomicrographs of immunohistochemical staining for CD68 (pan macrophages), 
CCR7 (M1 macrophages), and CD163 (M2 macrophages) in autologous, 14C-SIS, and 14C-X-SIS scaffold 
repair sites from saline-treated animals at one week post-surgery. Scale bar = 300 μm. 
 
A similar pattern of macrophage polarization was observed between the autologous tissue 
graft at one week and the 14C-X-SIS scaffold at one and two weeks for most treatment groups 
(Figure 29D). In contrast, the autologous tissue graft at two weeks and the 14C-SIS scaffold at 
one and two weeks were skewed toward the M2 (CD163+) phenotype for all treatment groups. 
The pattern of macrophage polarization for the treatment groups with respect to time showed that 
the remodeling sites of clodronate liposome-treated animals expressed a greater M2 (CD163+) 
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phenotype at two weeks compared to one week for the autologous and the 14C-SIS scaffolds, but 
not for the 14C-X-SIS scaffold. The remodeling sites from animals treated with PBS liposomes 
showed a switch from an M1 dominate to an M2 dominate phenotype at two weeks compared to 
one week for the autologous tissue graft, but no difference was observed between one and two 
weeks for the 14C-SIS or the 14C-X-SIS scaffolds. The graft sites from animals treated with saline 
showed a similar pattern of macrophage polarization between one and two weeks for all scaffold 
groups.  
A preliminary analysis failed to indicate any effects due to area or the interactions of area 
with other factors, so the data were aggregated over area. For the M1 ratio, no statistically 
significant effects were found for the percentage of M1 polarized cells. For the percentage of M2 
polarized cells, the statistically significant effects were the scaffold by time interaction (P<0.03). 
Further analysis of the M2 data indicated that there were no statistically significant differences in 
scaffolds at one week; but differences were evident at two weeks with 14C-SIS greater than 14C-
X-SIS. For the autologous scaffold, percentage of M2 cells at one week was less than percentage 
of M2 cells at two weeks.  No other comparisons were statistically significant. 
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 Figure 29: Percentage macrophage polarization at one and two weeks post-implantation of (A) autologous, 
(B) 14C-SIS, and (C) 14C-X-SIS scaffolds. All values are presented as mean ± SEM. For the percent of M1 
cells, no statistically significant effects were found. For the percent of M2 cells, the statistically significant 
effects were the scaffold by time interaction (P < 0.03). (D) The percentage of M1 (CCR7+) macrophages was 
subtracted from the percentage of M2 (CD163+) macrophages for each scaffold and treatment group at one 
and two weeks post-implantation. Positive values are indicative of an M1 type response while negative values 
are indicative of an M2 type response. 
 
5.2.6 Gene Expression Findings 
The expression of iNOS (M1) and ARG-1 (M2) was detected for all specimens. For the 
autologous tissue graft, the animals treated with saline showed low expression of iNOS and 
ARG-1 at one week, but by two weeks the iNOS and ARG-1 expression increased 1500 and 40-
fold, respectively (Figure 30A). For the animals treated with the clodronate or the PBS-filled 
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liposomes, the gene expression for iNOS showed similar levels, but the ARG-1 expression 
decreased, from one to two weeks. For the 14C-SIS scaffolds, the animals treated with PBS-filled 
liposomes showed little iNOS expression at one week but an increase by two weeks, but no 
appreciable change in ARG-1 expression was noted from one to two weeks. The ARG-1 
expression was higher for the saline-treated animals compared to the clodronate liposome-treated 
animals at one week (Figure 30B). The 14C-X-SIS scaffold showed no significance within the 
scaffold group for the iNOS and ARG-1 gene expressions for any treatment group (Figure 30C). 
 The gene expression markers iNOS and ARG-1 use opposing pathways for arginine 
metabolism and therefore the expression can be directly compared (see 2.1.2) (Figure 30D). 
There was a mixed expression of iNOS and ARG-1 for all implant groups treated with the 
clodronate liposomes with the exception of the M1 dominate profile of the autologous test article 
at two weeks post-implantation. The PBS liposome treated groups showed a mixed expression 
for most of the implant groups with the exception of the 14C-SIS scaffold group at one week and 
14C-X-SIS scaffold group at two weeks. The saline treated groups showed a ratio of iNOS:ARG-1 
that was skewed toward M2 polarization for the autologous tissue graft at one week and the 14C-
SIS scaffold at one and two weeks.  
 
 84 
 Figure 30: Gene expression of iNOS and ARG-1 relative to the housekeeping gene and the native abdominal 
muscle at one and two weeks post implantation of (A) autologous, (B) 14C-SIS, and (C) 14C-X-SIS scaffolds. 
All values are presented as mean ± SEM. * indicates statistical significance (p < 0.05) within a scaffold group. 
‡ indicates statistical significance (p < 0.05) between scaffold groups within a treatment group. (D) Ratio of 
iNOS:ARG-1 expression for each scaffold and treatment group at one and two weeks post-implantation. 
Values above 1.0 are indicative of a predominance of iNOS expression while values less than 1.0 are indicative 
of a predominance of ARG-1 expression. 
 
 The gene expression markers IFN-γ and IL-10 are known inducers of M1 and M2 
macrophages, respectively (see section 2.1.2) [108]. For the saline treatment group, the 
expression of IFN-γ increased in the autologous tissue graft but no change was detected for the 
14C-SIS and 14C-X-SIS scaffolds from one to two weeks (Figure 31A). At two weeks, the sites 
repaired with the autologous tissue graft showed greater IL-10 expression for the saline treated 
animals compared to 14C-SIS (Figure 31B). For the 14C-SIS scaffold group, the gene expression 
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of IL-10 decreased from one to two weeks for the saline treatment group, but no change was 
detected for the clodronate or PBS-liposome treated animals (Figure 31B). Additionally, the 
saline treatment group showed higher expression of IL-10 compared to the clodronate liposome-
treated group at one week (Figure 31B). 
 
 
Figure 31: Gene expression of (A) IFN-γ and (B) IL-10 relative to the housekeeping gene and the native 
abdominal muscle one and two weeks post-implantation for autologous, 14C-SIS, and 14C-X-SIS scaffolds. All 
values are presented as mean ± SEM. * indicates statistical significance (p < 0.05) within a scaffold group. ‡ 
indicates statistical significance (p < 0.05) between scaffold groups within a treatment group. 
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5.3 DISCUSSION 
The results of Specific Aim 2 confirm the intuitive concept that blood-derived mononuclear 
macrophages play a necessary and important role in the early in vivo degradation process of 
ECM scaffolds and autologous tissue grafts, and that chemical crosslinking of the ECM by 
compounds such as CDI effectively inhibit the degradation process. These findings are important 
in the context of regenerative medicine and biologic scaffolds because the proposed mechanisms 
of the constructive remodeling response typically require scaffold degradation to realize the 
optimal beneficial effects. Degradation-dependent events such as the release of constituent 
growth factors, the production and release of matricryptic peptides and the recruitment of host 
progenitor cells and stem cells contribute to the well-documented dynamic histomorphologic 
changes that characterize the host response to such scaffold materials during this early post 
operative period [5, 7, 8, 36, 48, 49, 53, 55, 95, 96]. It is logical to speculate, based upon the 
results of the present study, that blood derived mononuclear macrophages are at least important, 
if not essential, mediators of these degradation dependent events. Such an interpretation is in 
stark contrast to the conclusion that a macrophage-rich tissue response following ECM scaffold 
implantation necessarily represents an adverse host-patient reaction [172].  Since the presence of 
mononuclear macrophages is usually associated with inflammatory processes and the expected 
downstream consequences of tissue necrosis and scar tissue formation, the findings of the present 
study emphasize the wisdom of evaluating the role of macrophages with an open mind at least 
with regard to ECM scaffold remodeling.  
The host tissue response to a biomaterial is, by definition, the central factor in the 
eventual remodeling outcome. In a study described in Section 2.2, chemical crosslinking of the 
SIS scaffold with CDI resulted in a switch from an M2 dominant profile to an M1 dominant 
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profile and a change in the long-term (16 week) remodeling outcome from constructive 
remodeling to chronic inflammation [60]. The M2 response was associated with an organized, 
site-appropriate tissue remodeling outcome and an absence of persistent inflammation. CDI-
crosslinking was associated with an M1 response, long-term inflammation and the formation of 
multinucleate giant cells and scar tissue. The present study showed that CDI effectively inhibited 
ECM scaffold degradation regardless of the presence of macrophages; in addition, the 
macrophages present at the remodeling site of 14C-X-SIS for all treatment groups showed a 
mixed M1/M2 phenotype, and less M2 (CD163+) macrophages compared to 14C-SIS. This 
finding was not unexpected and was consistent with recent studies that show a markedly altered, 
proinflammatory host tissue response to ECM scaffolds that were chemically crosslinked [42].   
In the present study, it was observed for the noncrosslinked scaffolds that by two weeks 
the treatment with clodronate liposomes resulted in a host tissue response, but not macrophage 
cell surface marker expression, that skewed more toward a type I profile compared to the saline 
treatment groups. Stated differently, the systemic depletion of monocytes resulted in an altered 
remodeling response for the autologous and 14C-SIS scaffolds, which may be at least partly due 
to the remaining cell populations that participated in the host response. Although not directly 
investigated in this study, the depletion of macrophages would logically alter the temporal and 
spatial response of other cell types towards an implanted scaffold material, including ECM 
scaffolds. The acute host tissue response to an implanted foreign material, as all of these 
materials represent, is typically characterized by the presence of neutrophils. After three to five 
days, the neutrophil population decreases and the mononuclear macrophage population becomes 
the predominant cell response. This balance of neutrophil departure and mononuclear 
macrophage arrival was disrupted by the depletion of macrophages in the present study. 
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Neutrophils were still the prominent feature of the host cell response two weeks following 
implantation in the animals that were implanted with the 14C-SIS scaffold and that received 
clodronate-containing liposomes. The present results show that neutrophils do indeed participate 
in ECM scaffold remodeling, but do not appear to be major determinants of early scaffold 
degradation based upon the quantitative 14C measurements. It is logical that at least a certain 
degree of neutrophil-mediated scaffold degradation should occur but the ability of neutrophils 
alone to provide for all of the biologic effects that are associated with ECM scaffold degradation 
remains to be investigated. 
In summary, macrophages play an important and central role in biologic scaffold 
degradation and remodeling. Their presence within and surrounding scaffold materials following 
in vivo implantation should not only be expected but perhaps recognized as a favorable course of 
events and may predict a constructive remodeling outcome. 
5.4 CONCLUSIONS 
Macrophages that populated the 14C-SIS scaffold following in vivo placement were at least 
partially responsible for scaffold degradation. The CDI crosslinking agent used to manufacture 
14C-X-SIS inhibited macrophage mediated scaffold degradation. The depletion of macrophages 
at the sites of 14C-SIS, 14C-X-SIS, and autologous graft implantation resulted in an attenuation of 
the host inflammatory response and slowed the rate of scaffold degradation. These findings show 
that macrophages are important contributors to biologic scaffold degradation and early 
remodeling events. 
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5.5 LIMITATIONS AND FUTURE WORK 
There were several limitations in the present study. First, the determination of M1 versus M2 
phenotype was based upon a limited number of cell surface markers. Although many markers 
exist to differentiate between M1 and M2 macrophages for murine and human tissues, most of 
these same markers are not available for the analysis of rat tissue, especially formalin-fixed 
tissue. Second, the results were confined to the early stages of scaffold remodeling; that is, two 
weeks. The marked depletion of mononuclear macrophages for longer periods of time places the 
host at great risk for sepsis and makes such studies difficult. Furthermore, repeated 
administration of clodronate was performed in order to insure that the results were not 
confounded by newly formed circulating macrophages later in the study period.  It should also be 
noted that the present study is limited to a single type of biologic scaffold material, specifically 
the SIS, but the learned principles may be applicable to all biologic scaffold materials.  
The present study characterized the macrophage population that participated in the 
remodeling response as a function of the M1 and M2 polarization schemes in a rat model. The 
sum of M1 and M2 immunopositive cells did not always equal the number of CD68 
immunopositive cells [171]. It should be noted that CD68+ macrophages that were not yet 
determined to be an M1 or M2 phenotype would remain negative for the respective markers. It is 
presently not known what percentage (i.e., threshold) of M1 or M2 cells is required to influence 
the formation of scar tissue formation or constructive remodeling response, respectively. It is 
hypothesized in the present study that the comparison of M1 vs. M2 may be more important than 
the absolute number of cells or the absolute gene expression.  There is a clear correlation of the 
M1/M2 relationship to remodeling outcomes in previous studies that investigated the remodeling 
response beyond two weeks [60, 151]. 
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6.0  SPECIFIC AIM 3: TO DETERMINE THE HISTOMORPHOLOGY AND 
FUNCTIONALITY OF SIS-ECM SCAFFOLDS WHEN USED FOR THE 
RECONSTRUCTION OF MUSCULOSKELETAL TISSUE IN A RAT MODEL   
6.1 INTRODUCTION 
The biomechanical and biochemical properties of ECM scaffolds have been extensively 
characterized [52, 125, 173-175], but inevitably change after implantation due to the concurrent 
processes of scaffold degradation and host neomatrix deposition and remodeling [97, 99, 176]. 
Arguably, one of the most important merits for clinical success following use of an ECM 
scaffold is the functionality of the newly formed tissue. The functionality of remodeled ECM has 
been investigated in tendinous tissues, with the results showing a initial decrease in strength after 
implantation as the scaffold begins to degrade, followed by an increase in strength as new host 
tissue deposition occurs [35, 38, 44, 98]. However, no studies have quantitatively assessed the 
active contractility of remodeled ECM scaffold after repair of skeletal muscle tissue.  
A previous study using the same animal model and the same test articles investigated the 
morphologic changes and the macrophage phenotype up to 16 weeks post-surgery, but did not 
explore the functional properties of the reconstructing tissue (see Sections 2.2.1.2 and 2.2.2.1) 
[42, 60]. The histomorphologic and active contraction experiments of Specific Aim 3 will 
complement and further characterize the remodeling response and associate the macrophage 
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phenotype during the early stages of the remodeling process to the downstream structural and 
functional properties of the reconstructed tissue. The objectives of Specific Aim 3 were: (1) to 
determine the functionality of skeletal muscle tissue that was repaired with one of three clinically 
relevant and commercially available test articles in a rat model; and (2) to characterize the 
histomorphologic appearance of the remodeled tissue.  The hypothesis is that functional tissue 
will result from an outcome of constructive remodeling after repair with noncrosslinked scaffolds 
versus chronic inflammation after repair with crosslinked scaffolds. 
6.2 MATERIALS AND METHODS 
6.2.1 Overview of Experimental Design 
Twenty-four male Sprague Dawley adult rats were randomly assigned to three groups of eight. 
Each rat was subjected to surgical partial thickness excision of a 1.5 cm x 1.5 cm section of the 
ventral lateral abdominal wall musculature. The defect was repaired with one of three test 
articles: Restore™, a 10 layer configuration of an ECM biologic scaffold composed of porcine 
SIS (n = 8); CuffPatch™, a 10 layer configuration of porcine SIS that was manufactured with 
CDI as a crosslinking agent (n = 8); or autologous body wall tissue (n = 8). The animals were 
survived to 26 weeks. The contractile properties of the remodeled tissue and of the contralateral 
native tissue were determined in-situ immediately prior to euthanasia. Following euthanasia and 
explantation of the remodeled scaffold materials, histologic and immunolabeling methods were 
used to determine the morphologic characteristics including the distribution of slow (Type I) and 
fast (Type II) skeletal muscle fibers, blood vessels, and nerves. 
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6.2.2 Test Articles 
The ECM-derived scaffold materials that were used to repair the surgically created defect were 
derived from porcine SIS and differed mainly by the processing methods, i.e., the use of a 
chemical crosslinking agent. The Restore™ (DePuy Orthopaedics Inc., IN) device represents an 
ECM scaffold material that is not subjected to chemical crosslinking. The CuffPatch™ 
(Arthrotek, Inc., Warsaw, IN) device represents an SIS material that is crosslinked with CDI. 
Both of the ECM materials were purchased from the manufacturer. The handling of the materials 
after removal from the sterile package and prior to surgical implantation was performed 
according to the manufacturer’s instructions as provided in the package insert. Skeletal muscle 
tissue excised from the abdominal wall of each animal in the last group served as the autograft.   
6.2.3 Animal Care Compliance 
All procedures were performed in accordance with the National Institute of Health (NIH) 
guidelines for care and use of laboratory animals, and with approval of the Institutional Animal 
Care and Use Committee (IACUC) at the University of Pittsburgh.   
6.2.4 Animal Source and Husbandry 
Twenty-four adult male Sprague-Dawley rats weighing approximately 300 grams were 
purchased from Charles River Laboratory (Wilmington, MA). Each animal was housed 
individually in shoebox cages. The rats were fed a diet of Purina Isopro rodent chow ad libitum 
(LabDiet ProLab Isopro RMH 3000, PMI Nutrition International, St. Louis, MO). The housing 
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environment was maintained at 68° to 76°C for twenty four hours a day and with a light:dark 
cycle of 12:12 hours.   
6.2.5 Surgical Procedure 
The partial thickness abdominal wall defect model for evaluation of muscular tissue remodeling 
was detailed in Section 5.1.5 but is briefly reviewed herein. Each animal was anesthetized by 
inhalation with 2% isoflurane in oxygen. The surgical site was prepared for sterile surgery. A 
ventral midline abdominal skin incision was created, and the skin and subcutaneous tissue were 
separated from the underlying muscle tissues on one side of the midline. A 1.5 cm x 1.5 cm 
section of the external and internal oblique layers of the ventral lateral abdominal wall was 
excised; the underlying transversalus fascia and peritoneum remained intact. The defect was 
repaired with a size-matched piece of the chosen test article. A single 4-0 Prolene suture was 
placed at each of the four corners of the test article to secure the device to the surrounding 
musculature, allow for mechanical loading of the test article, and to demarcate the implant for 
identification at the time of in-situ functional testing and necropsy. A subcuticular placement of 
4-0 Vicryl suture was used to close the skin incision. Each animal was recovered from anesthesia 
and was returned to the housing unit.  
Each rat received 0.02 mg Buprenex (buprenorphine hydrochloride) by subcutaneous 
injection the day of surgery and for two additional days. Baytril (20 mg) was given orally the day 
of surgery and for two additional days. The dietary habits, general health status, and the surgical 
site were monitored daily and recorded. 
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6.2.6 Measurement of Contractile Force In-Situ 
6.2.6.1 Muscle Flap Preparation  
Twenty-six weeks after the initial surgical procedure, each animal was prepared for functional 
testing of the implant site. Each rat was anesthetized with 2% isoflurane in oxygen by inhalation. 
A midline skin incision was created, and the skin and overlaying fascia was dissected from the 
underlying body wall at the site of test article implantation. The remodeled site was identified by 
the preplaced Prolene sutures at the four corners of the test article. A flap of tissue was created 
which contained the remodeled site plus 2 mm of adjacent native musculature. The origin and rib 
attachment of the external oblique muscle remained intact to maintain blood flow and 
innervation to the remodeled test article site. The muscle fibers on the remaining sides of the 
implantation site, including the insertion site at the linea alba were dissected free of all adjacent 
tissue attachment to isolate the tissue for contractile testing. The contralateral site, which did not 
receive a test article and was not surgically modified, was prepared in identical fashion to serve 
as a control for each animal (Figure 32).  
The isolated tissue flap was positioned such that the direction of the muscle contraction 
was aligned along an axis from the costochonral arch toward the linea alba. Platinum electrodes 
were placed across the flap of tissue perpendicular to the direction of muscle contraction and at 
both the proximal and distal ends of the scaffold placement site as identified by the Prolene 
sutures. The distal (previous insertion end) tissue was secured to a force transducer (Sensotec, 
Columbus, OH; model 31) with silk suture. An analog to digital data acquision card (National 
Instruments [NI], Austin, TX; PCI-6023E) received signals from the force transducer (Figure 
32). A custom-designed program was created in LabVIEW software (National Instruments) to 
monitor and record the forces measured by the force transducer.  
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 Figure 32: Representative schematic of the apparatus used to measure in situ tetanic force generation. Top 
illustration: the musculoskeletal defect was created by excising the external and internal oblique layers of the 
abdominal wall, leaving the transversalus fascia intact. Middle illustration: the test article was implanted in 
the defect site and secured with Prolene sutures at each of the four corners. Bottom illustration: twenty-six 
weeks post-implantation, a flap of tissue was created which contained the site of test article placement, 
identified by the preplaced Prolene sutures. The tissue flap maintained the muscular arteries and the thoracic 
spinal nerve branches that supplied the site of tissue remodeling. The muscle fibers on the remaining sides of 
the implantation site, including the insertion site at the linea alba, were dissected free from the surrounding 
adjacent tissue. The distal end of the flap was connected to the force transducer with silk suture, and 
positioned such that the direction of the function testing was aligned parallel to the rib origin. Platinum 
electrodes were placed across the flap proximal and distal to the scaffold placement site. 
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6.2.6.2 Contractile Force Testing  
The isolated tissue flap was stimulated with a S88X Grass stimulator (Astro-Med, Inc., West 
Warwick, RI). Optimum length Lo was determined as the length at which the maximum twitch 
force was obtained using a 2 ms pulse at 50 pulses per second (pps). The maximum tetanic force 
(Pt-MAX) for the test site (Pt,S) and the contralateral native tissue (Pt,N) as a function of 
stimulation rate was determined by delivering 5, 10, 15, 20, 30, 40, 60, and 75 pps in 1-second 
trains with 2 minutes of rest between each test. The Pt,S was normalized to Pt,N and to the native 
Pt-MAX (Pt,N-MAX). The contractile force for each stimulation frequency was then calculated 
for each tetanic force and specific force was calculated for Pt-MAX by normalizing with the 
cross-sectional area of the tissue.  
6.2.6.3 Fatigue Resistance Testing  
The fatigue resistance of the tissue at the test site was determined by comparing the force 
generated at time t = 0 to t = 2 minutes. After a five minute rest period, pulses were delivered at 
the frequency at which the forces plateau during the tetanic force testing, in trains of 330 ms 
duration at a rate of 1 train per second, for a total of two minutes. The Fatigue Index was 
calculated as the ratio of the residual force at t = 2 to the initial force at t = 0.  
6.2.7 Euthanasia and Specimen Harvest   
Following completion of the functional testing, each rat was euthanized with 5% isoflurane in 
oxygen followed by an intracardiac injection of 5 mL of potassium chloride to induce cardiac 
arrest. The muscle flap was excised at the rib origin, mounted on a fixed support structure to 
maintain the size and shape of the tissue, and placed in 10% neutral buffered formalin (NFB).  
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6.2.8 Histologic and Immunohistochemical Analysis 
The NBF-fixed specimens were sectioned perpendicular to the direction of contractile function 
testing at the implantation site in four separate locations. The tissue was embedded in paraffin, 
cut into 6-µm thick sections, and mounted for H&E or Masson’s trichrome staining and 
immunohistochemical analysis. The primary antibodies used for immunohistochemical staining 
were: (1) monoclonal antimyosin (skeletal, slow, clone NOQ7.5.4D; Sigma-Aldrich, St. Louis, 
MO) at 1:4000 dilution for identification of slow (type I) skeletal muscle fibers; (2) monoclonal 
antimyosin (skeletal, fast, alkaline phosphatase conjugate, clone MY-32, Sigma-Aldrich) at 
1:200 dilution for identification of fast (type II) skeletal muscle fibers; (3) rabbit polyclonal von 
Willebrand factor (Abcam, Cambridge, MA) at 1:1000 dilution for identification of endothelial 
cells and blood vessels; and (4) anti-neurofilament (DakoUSA, Carpinteria, CA) at 1:100 
dilution for identification of neurons. The secondary antibodies used were biotinylated anti-
mouse IgG (H+L, rat absorbed) (Vector, Burlingham, CA) at 1:200 dilution, and goat anti-rabbit 
IgG (H+L, rat absorbed) (Vector) at 1:200 dilution. NBF-fixed rat skeletal muscle tissue from the 
native abdominal wall was used as the positive control tissue for slow and fast antimyosin and 
for anti-neurofilament, and NFB-fixed rat liver was used as the positive control tissue for von 
Willebrand factor. 
The antibodies to the fast and slow skeletal muscle fibers were visualized with two 
substrate staining systems on each section. Separate tissue sections were used for the von 
Willebrand factor and neurofilament staining.  
The following protocol was used to identify fast and slow muscle fibers. Unstained 
sections were deparaffinized with xylene and rehydrated through a graded ethanol series. Heat-
mediated antigen retrieval was performed with 0.1 mM EDTA buffer at 95-100 ºC for 25 
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minutes. After cooling for 15 minutes, enzyme-mediated antigen retrieval was performed with 
0.1% trypsin/0.1% calcium chloride digestion at 37ºC for 10 minutes. Three washes in TBS, pH 
7.6, were then performed. The slides were incubated for 10 minutes in a blocking solution 
containing 2% normal horse serum (Vector) and 2% normal goat serum (Vector) at room 
temperature to prevent non-specific antibody binding. To inhibit endogenous peroxidase activity, 
the slides were incubated with 3% hydrogen peroxide (Spectrum) in methanol for 10 minutes at 
room temperature. The slow anti-myosin antibody was applied for 30 minutes at room 
temperature. The slides were then incubated with the secondary antibody for 30 minutes at room 
temperature, followed by horseradish peroxidase solution (Vector) for 30 minutes at 37ºC. 
Diaminobenzidine (DAB) (Vector) was applied to detect positive staining cells. The blocking 
solution was then applied again for 10 minutes at room temperature, followed by the fast anti-
myosin antibody for 60 minutes at room temperature. Red alkaline phosphatase substrate was 
applied to detect positive staining.   
The following protocol was used to stain for von Willebrand factor and neurofilament. 
After deparaffinization and rehydration of the sections as described above, heat-mediated antigen 
retrieval was performed with 0.01M citrate buffer (Spectrum, New Brunswick, NJ), pH 6.0, at 
95-100 ºC for 20 minutes. After cooling for 15 minutes, enzyme-mediated antigen retrieval was 
performed for the staining of von Willebrand factor using proteinase K in a buffer of 50mM Tris 
base and 1 mM EDTA, pH 8.0, at 60ºC for 10 minutes. Three washes in PBS were then 
performed. The slides were incubated for 30 minutes with 2% normal horse serum (Vector) at 
37ºC to prevent non-specific antibody binding. To inhibit endogenous peroxidase activity, the 
slides were incubated with 3% hydrogen peroxide (Spectrum) in methanol for 30 minutes at 
room temperature. The slides were incubated with the secondary antibody for 30 minutes at 
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37ºC, followed by horseradish peroxidase solution (Vector) for 30 minutes at 37ºC. DAB 
(Vector) was applied to detect positive staining cells and the slides were counterstained with 
hematoxylin.  
6.2.9 Statistical Analysis 
A one-way analysis of variance (ANOVA) was performed, followed by the Tukey’s post hoc test 
to determine significant differences between test articles for Pt-MAX, Specific Force, Fatigue 
Index, and the quantitative immunohistochemical analysis of blood vessels and muscle fibers. A 
p value of less than 0.05 was considered to be significant. 
6.3 RESULTS 
No complications occurred during the procedure, and all animals survived to the assigned 
timepoint of 26 weeks.  
6.3.1 Contractile Properties of Remodeled Tissue 
Tetanic contractile responses were observed in all of the contralateral native tissue specimens 
and all of the tissue specimens that were harvested from sites in which the Restore device was 
implanted (Figure 33). The tissue repaired with the Restore device generated approximately 82% 
of the tetanic force of native tissue (Figure 34, Figure 35). When normalized for cross-sectional 
area, the specific forces of the tissue repaired with Restore were similar to the native tissue 
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(Figure 36, Table 7). Four out of eight specimens harvested from the sites in which the CuffPatch 
device was placed and six out of eight specimens harvested from sites in which the autologous 
graft was placed generated a tetanic response (Figure 33). The CuffPatch device and the 
autologous tissue graft sites showed approximately 11% and 61%, respectively, of the tetanic 
force of native tissue (Figure 34, Figure 35).   
The Fatigue Index for the native tissue was significantly lower than for the site implanted 
with the Restore device, despite the similar values for specific force (P = 0.93). The sites 
implanted with the CuffPatch device and the Restore device showed similar Fatigue Index values 
(P = 0.62), while the native tissue and sites implanted with the autologous tissue graft showed 
similar Fatigue Index values (P = 0.67) (Table 7). 
 
 
Figure 33: In situ muscle contraction studies were performed on muscle flaps from implants at 26 weeks post-
surgery and compared to contralateral, native muscle. The tetanic forces (N) generated by remodeled and 
native tissue following electrical stimulation between 5 and 75 pps. Data expressed as mean ± standard error. 
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 Figure 34: The percent tetanic force of the remodeled tissue compared to the contralateral native tissue with 
respect to the tetanic force at each stimulation frequency. Data expressed as mean ± standard error. 
 
 
Figure 35: The percent tetanic force of the remodeled tissue compared to the contralateral native tissue with 
respect to the maximum tetanic force. Data expressed as mean ± standard error. 
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 Figure 36: Contractile forces (N/cm2) of tissue, which peaked at 40 pps for the native tissue, and 50 pps for 
the remodeled tissue. Data expressed as mean ± standard error. 
 
Table 7: The contractile properties for each scaffold group and the contralateral native tissue. 
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6.3.2 Histomorphologic and Immunolabeling Findings 
6.3.2.1 Native tissue  
The native tissue harvested from the contralateral abdominal wall showed myofibers that were 
organized into muscle bundles, with sparse collagenous connective tissue and adipose connective 
tissue (Figure 37). Mature blood vessels and capillaries (Figure 41A) and nerve fibers (Figure 
41E) were located adjacent to the muscle bundles. The number of blood vessels and muscle types 
(i.e., slow type I and fast type II) were quantified by positive immunostaining (Table 8). The 
native tissue showed fewer blood vessels and a high density of fast type II and slow type I fibers 
compared to all other test articles. The majority of the myofibers were immunopositive for fast 
type II myosin, and the fibers that stained positive for slow type I myosin were evenly distributed 
between the fast fibers (Figure 42A). 
 
 
Figure 37: At 26 weeks post surgery, the native tissue was composed mainly of muscle cells organized into 
tight bundles and mature blood vessels and nerves (arrows) were adjacent to the muscle bundles. Tissue 
sections were stained with Masson’s trichrome. Higher magnification image was acquired from the lower 
magnification image in the area outlined by the rectangle. Scale bars = 300 μm. 
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6.3.2.2 Restore device  
The sites in which the Restore device was placed showed no histologic evidence of the originally 
implanted device 26 weeks after implantation and replacement with new host tissue that 
contained organized bundles of skeletal muscle cells, and partially organized collagenous 
connective tissue and adipose connective tissue surrounding the muscle bundles (Figure 38). 
There was no evidence of chronic inflammation. A moderate number of mature vessels and 
capillaries (Figure 41B, Table 8) and nerve fibers (Figure 41E) were located adjacent to the 
muscle bundles. Similar to the native tissue, the majority of the muscle fibers stained positive for 
fast type II myosin, and the muscle fibers that stained positive for slow type I myosin were 
dispersed equally alongside the fast fibers (Figure 42B, Table 8).  
 
 
Figure 38: At 26 weeks post implantation, the Restore device completely remodeled into new host tissue 
which was comprised of bundles of muscle fibers surrounded by vascularized, organized collagenous 
connective tissue. Tissue sections were stained with Masson’s trichrome. Higher magnification image was 
acquired from the lower magnification image in the area outlined by the rectangular. Scale bars = 300 μm. 
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6.3.2.3 CuffPatch device  
At 26 weeks, the surgical site in which the CuffPatch device was placed showed that remnants of 
the original device were surrounded by mononuclear cells and multinucleate giant cells (Figure 
39). The tissue surrounding the implantation site contained a robust capillary presence (Figure 
41D, Table 8) and densely organized collagenous connective tissue. Neurons were identified 
adjacent to the blood vessels at the host-implant interface (Figure 41G). No nerve fibers were 
identified within the implantation site. The muscle fibers showed a low density of fast type II 
fibers, which were located peripheral to the site of scaffold placement (Figure 42C, Table 8). 
 
 
Figure 39: After 26 weeks post surgery, the tissue treated with the CuffPatch device contained identifiable 
remnants of the originally implanted device (*), which were surrounded by dense collagenous tissue, 
numerous blood vessels, and inflammatory cells including multinucleate giant cells. Tissue sections were 
stained with Masson’s trichrome. Higher magnification image was acquired from the lower magnification 
image in the area outlined by the rectangle. Scale bars = 300 μm. 
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6.3.2.4 Autologous tissue graft  
The sites in which the autologous tissue graft was placed showed replacement of the graft by 
islands of muscle fibers that were surrounded by a moderate amount of collagenous connective 
tissue and adipose tissue (Figure 40). There was no evidence of chronic inflammation. The new 
muscle bundles and adipose tissue contained nerve fibers and a moderate amount of mature 
blood vessels and capillaries (Figure 41D, Figure 41H, Table 8). There was a high density of fast 
type II fibers, and the slow type I muscle fibers were organized in clusters among the fast type II 
muscle fibers (Figure 42D, Table 8). 
 
 
Figure 40: At 26 weeks post surgery, the tissue treated with the autologous graft showed randomly dispersed 
muscle bundles surrounded by fibrous connective tissue and adipose connective tissue. Tissue sections were 
stained with Masson’s trichrome. Higher magnification image was acquired from the lower magnification 
image in the area outlined by the rectangle. Scale bars = 300 μm. 
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Figure 41: Blood vessel 
distribution and innervation of 
native and remodeled tissue. 
Tissue sections at 26 weeks post 
surgery were immunolabeled 
for Von Willibrand Factor to 
identify endothelial cells 
associated with the lumen of 
blood vessels (A-D), and anti-
neurofilament was used to 
identify nerve structures (E-H) 
in the native and remodeled 
tissue sections. Mature blood 
vessels (A) and nerves (E) were 
located adjacent to the muscle 
bundles for the native tissue. 
The tissue repaired with the 
Restore device (B,F), and the 
tissue repaired with the 
autologous graft (D,H) showed 
nerves adjacent to the new 
muscle cells, and larger blood vessels were identified throughout the implantation site. The remnants of the 
original CuffPatch device (indicated by *) (C) were surrounded by a substantial amount of capillaries and 
larger vessels; individual neurons were located in close proximity to new blood vessels that surrounded the 
remnants of the CuffPatch device (G). Scale bars = 300 μm. 
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 Figure 42: Distribution of slow and fast skeletal muscle fibers in native tissue and remodeled tissue at 26 
weeks post surgery. Tissue sections were double-labeled for antimyosin slow (type I) skeletal muscle (brown 
stain) and antimyosin fast (type II) skeletal muscle (red stain). The native tissue (A) and the tissue repaired 
with the Restore device (B) showed that the slow muscle fibers were uniformly distributed between the fast 
muscle fibers. Skeletal muscle fibers surrounded the proximal edges of the CuffPatch device (C) but were not 
located within the graft site. (D) In the autologous tissue graft, the slow muscle fibers were distributed in an 
irregular pattern among the fast muscle fibers in the remodeling site, in that the slow fibers were sporadically 
distributed in some areas and arranged in clusters for other areas. Scale bars = 300 μm. 
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Table 8: Quantitative IHC analysis for each scaffold group and the contralateral native tissue 
 
 
6.4 DISCUSSION 
Surgical mesh remodeling has commonly been assessed by passive mechanical characteristics, 
such as ultimate tensile strength, failure load, tangent modulus, and stiffness when used for the 
repair of tissues such as tendons and ligaments [99, 176-178] but repair of muscular tissue 
requires assessment of the active contractile force of the repair site to determine whether function 
is restored [18, 179].  
Sections 2.2.1.2 and 2.2.2.1 showed that tissue remodeled with non-crosslinked SIS 
elicited a macrophage phenotype indicative of a tissue remodeling (M2) response in the early 
remodeling period, and constructive remodeling was the consequential outcome. Alternatively, 
tissue remodeled with CDI-SIS elicited predominately a pro-inflammatory macrophage (M1) 
response by four weeks after surgical placement, and resulted in chronic inflammation and the 
deposition of dense connective tissue and/or scarring. The histomorphologic and active 
contraction results of the current study support the hypothesis that functional tissue resulted from 
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an outcome of constructive remodeling after repair with noncrosslinked scaffolds versus chronic 
inflammation after repair with crosslinked scaffolds. 
The tissue engineering approach for muscle reconstruction typically uses a myogenic 
progenitor cell population such as mesenchymal stem cells or satellite cells, in combination with 
scaffolds that may or may not include bioactive factors to support growth and differentiation 
[180]. Synthetic scaffold materials such as polylactic-co-glycolic acid (PGA) have been designed 
with nano- or microscale topographic features [181] or maintained under tension [182] for the 
purpose of parallel alignment of myoblasts and cytoskeletal proteins, an important requirement 
for functional skeletal muscle. Organic conducting polymers such as polypyrrole have the 
potential to promote the differentiation of electrically excitable cell types such as myoblasts and 
nerves by transmitting electrical and mechanical stimulation directly to the cell surface [183]. A 
number of strategies have been applied to engineer contractile skeletal muscle tissue using in-
vitro or in vivo matrix-based approaches, but none have shown specific forces that approximate 
native muscle [184-186]. Pioneering work by Vanderburgh and colleagues [187] designed a 
mechanical cell stimulator device to apply mechanical stimulation to “human bioartificial 
muscles” (i.e., skeletal muscle cells suspended in Matrigel:collagen), resulting in improved 
myofibers diameter and alignment, increased elasticity of the muscle fibers, and improved cell-
generated passive force. A study by Borschel et al. showed that constructs that were composed of 
C2C12 myoblasts (satellite cells of C3H mice) seeded onto an acellular scaffold harvested from 
the mouse extensor digitorum longus muscle produced specific forces that were approximately 
5% of that observed for the native muscle after 3 weeks of culture [188]. In a similar fashion, 
Yoo and colleagues seeded primary human muscle precursor cells onto acellular bladder 
submucosa and subjected the constructs to cyclic strain for up to 4 weeks, followed by 
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subcutaneous implantation of the cell-seeded construct onto the latissimus dorsi of mice. This 
study demonstrated that specific forces of 1% of that observed for native latissimus dorsi were 
produced when the constructs were preconditioned in an in-vitro bioreactor [189]. The present 
study showed that vascularized, contractile skeletal muscle resulted from ECM scaffold 
reconstruction without prior cell or mechanical preconditioning.  
For successful reconstruction of muscle, the remodeled tissue must be vascularized, 
innervated, and contain aligned muscle fibers in the direction of stress. Previous studies have 
shown that ECM scaffolds can effectuate constructive remodeling in reconstruction models of 
skeletal [97], cardiac [18, 179], and smooth muscle repair [21, 27, 100, 190]. In a study 
conducted in our laboratory, a canine model of musculotendinous repair showed that SIS 
facilitated the regeneration of functional musculotendinous tissue, including innervated muscle 
that histologically and functionally resembled native muscle tissue following the catastrophic 
loss of the gastrocnemius muscle/Achilles tendon junction. In a retrospective study conducted by 
Agrawal and colleagues, nerve tissue, including mature nerve, immature nerve, and Schwann 
cells were identified in specimens repaired with a non-crosslinked ECM scaffold as early as 28 
days in a rat abdominal wall repair model and in specimens 91 days post-surgery from a canine 
model of esophageal repair [152]. In the current study, nerve tissue and blood vessels were found 
adjacent to the newly formed muscle bundles in tissues repaired with the non-crosslinked ECM 
scaffold and the autologous tissue graft, further supporting the hypothesis that ECM scaffolds 
can be used to facilitate the regeneration of muscular tissue for functional restoration.  
Skeletal muscle is usually made up of a mixture of types I and II muscle fibers, and the 
fiber type composition and distribution can affect the speed of contraction, fatigability, and 
degree of force production. Slow type I fibers have slower maximum shortening velocities, lower 
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force production, and are more resistant to fatigue when compared to fast type II fibers [180]. In 
adult Sprague Dawley rats, the muscles with the highest percentage of the slow type I fibers are 
the soleus (84%), adductor longus (87%), and quadratus femoris (87%); the muscles with the 
lowest percentage of type I fibers are the gastrocnemius muscle (superficial-white portion) 
(<0.1%), tibialis anterior (2.5%) and the extensor digitorum longus (5%) [191, 192]. In the 
present study, muscle fiber content from sites repaired with the non-crosslinked SIS scaffold 
showed similar percentages of slow type I fibers to the repair sites of the autologous tissue graft 
but a lower percentage of slow type I fibers compared to the native tissue. However, the 
noncrosslinked SIS device showed a higher fatigue resistance than the native tissue, a finding 
that contradicts the percentage slow type I fiber data. The CDI-SIS scaffold and the native tissue 
showed a similar slow type I fiber percentage, which may be due to the high slow type I fiber 
content found in the native tissue and the low fast type II fiber found at the repair site of the 
crosslinked SIS scaffold. For CDI-SIS, it is most likely that the force generated and the fatigue 
index both indicate the influence of the surrounding native muscle and the new muscle that 
formed only peripherally to the scaffold, rather than specific characteristics of the site of 
remodeling. Furthermore, although statistical significance was detected between the scaffold 
groups, the percentage of slow type I fibers were within a range of 20 – 30%, a finding that is 
consistent to data reported by Delp and Duan [191]. In the present study, the percentage of slow 
type I fibers did not show a clear relationship with the fatigue index values, suggesting that the 
fiber type distribution may not have reached a certain threshold percentage to affect the fatigue 
resistance in a meaningful way. 
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6.5 CONCLUSION  
We have shown that non-crosslinked ECM scaffolds remodeled into functional skeletal muscle 
tissue that produced a contractile response and histomorphologic characteristics that were similar 
to the native muscle, including the presence of newly formed muscle fibers and nerve tissue. By 
introducing a crosslinking agent into the manufacturing protocol, the contractile response was 
drastically reduced, and the histomorphologic profile represented a foreign body reaction rather 
than a reconstructive response.     
6.6 LIMITATIONS AND FUTURE WORK 
A limitation to the current study was the lack of temporal evaluation of the contractile response 
to the scaffolds. Previous studies using the same animal model have investigated the 
morphologic changes of the scaffolds up to 16 weeks post-surgery, but did not explore the 
functional properties of the reconstructing tissue (see Appendix A) [36, 42, 151]. The 
histomorphologic and active contraction results of the current study support the hypothesis of the 
previous studies, in that functional tissue resulted from an outcome of constructive remodeling 
after repair with noncrosslinked scaffolds versus chronic inflammation after repair with 
crosslinked scaffolds.  
It is unclear whether the regenerative capacity of the remodeling tissue observed after 
ECM scaffold repair in the current study resulted from the local activation of satellite cells or 
muscle-derived stem cells [193], the homing and differentiation of early myeloid precursors from 
the bone marrow to the site of injury [193], the physical and biochemical signals released by the 
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degrading ECM scaffold while subjected to mechanical load, or a combination of the 
aforementioned. The source of cells that participated in the remodeling of new contractile 
skeletal tissue was not a focus of the current study, but would be an interesting endeavor for 
future investigations. 
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7.0  DISSERTATION SYNOPSIS 
This dissertation examined macrophage phenotype in the context of constructive remodeling 
with ECM scaffold remodeling, and attempted to correlate the remodeling events in the early 
post-operative period to downstream remodeling outcomes. Such an analysis is critical to 
understand the role that regenerative medicine plays in the efforts to change the default healing 
mechanism of scar tissue formation into reconstruction and functionality.  
In Specific Aim 1, the phenotype of monocyte-derived macrophages cultured on the 
surfaces of noncrosslinked SIS showed a phenotype that resembled a type 2 response, while the 
presence of chemical crosslinking to the same SIS scaffold changed the macrophage phenotype 
to a type 1 response. It was also discovered that low oxygen tension did not alter the gene 
expression and the protein secretion of most markers important to the differentiation of 
macrophages toward a type 1 or 2 response. In Specific Aim 2, the systemic depletion of 
monocytes in vivo showed that macrophages are necessary for the degradation of noncrosslinked 
ECM scaffolds, and that the tissue remodeling response was skewed toward a type 1 response. 
This study also showed that other cell types, including neutrophils, are affected at least in their 
temporal response pattern when macrophages are depleted from the surgical site. Specific Aim 3 
showed that the interpretation of constructive remodeling as an outcome to ECM scaffold 
placement correlated with active contractile functionality of the reconstructed tissue.       
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It is currently unknown whether macrophages uncommitted to either the M1 or M2 
phenotype were recruited to the site of scaffold remodeling and then stimulated to differentiate 
locally, or whether phenotype-committed macrophages were selectively recruited to sites of 
remodeling depending upon the antigens or substrates that were present. In either case, the 
findings of this dissertation suggest that strategies for tissue engineering and regenerative 
medicine that promote an M2 response are associated with a favorable remodeling response. 
Therefore it is important not only to consider the simple presence of macrophages at the site of 
scaffold remodeling but also the phenotype of this important cell population when attempting to 
predict downstream remodeling outcomes. 
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APPENDIX A 
EXTRACELLULAR MATRIX BIOSCAFFOLDS FOR ORTHOPAEDIC 
APPLICATIONS: A COMPARATIVE HISTOLOGIC STUDY 
ECM scaffolds differ in their species and tissue of origin, methods of processing, and methods of 
terminal sterilization. The purpose of this study was to evaluate the host tissue morphologic 
response to five commercially available ECM-derived biologic scaffolds used for orthopaedic 
soft tissue repair in a rodent model. The temporal sequence of remodeling events, including the 
rapidity of scaffold degradation and extent of new tissue deposition by the host, would logically 
be predictive of the clinical course, determination of the optimal rehabilitation protocol, and 
functional outcome. 
A.1 INTRODUCTION 
During the past decade, off-the-shelf biologic scaffold materials composed of ECM have become 
available for the repair and reconstruction of damaged or missing orthopaedic soft tissues. The 
clinical products currently available include GraftJacket® (Wright Medical Technology, Inc., 
Arlington, TN), Restore™ (DePuy Orthopaedics®, Inc., Warsaw, IN), CuffPatch™ (Arthrotek®, 
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Warsaw, IN), TissueMend® (TEI Biosciences, Inc., Boston, MA), and Permacol™ (Tissue 
Science Laboratories plc. Covington, GA). Each of the above-mentioned ECM-derived scaffold 
materials has been the subject of pre-clinical studies but little clinical outcome data is available; 
the partial cause of which is the relatively recent market introduction of these devices. These 
ECM-based products differ in the source species, tissue of origin, and the processing and 
sterilization procedures used to prepare each material for human clinical use. It is not clear how 
these differences can alter the host tissue remodeling response, clinical course and clinical 
outcome.   
A.2 MATERIALS AND METHODS 
A.2.1 Overview of Study Design  
One hundred twenty-six rats were randomly divided into six equal groups of twenty-one. Each 
rat was subjected to surgical excision of a 1.0-cm2 section of the musculotendinous portion of the 
ventral lateral abdominal wall leaving the abdominal fascia, transversus abdominis, and 
peritoneum intact. The defect was then repaired with one of five different ECM-derived scaffold 
materials or autologous tissue, depending upon the assigned group. The animals in each group 
were subdivided into seven subgroups based upon survival time: 2, 4, 7, 14, 28, 56 or 112 days. 
The surgical site plus an equal amount of surrounding tissue was collected at the time of sacrifice 
for histological examination. 
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A.2.2 Test Articles 
The five ECM-derived scaffold materials that were used to repair the surgically created defect 
were all derived from biologic sources and differed in species of origin, tissue of origin, 
processing methods, and/or method of terminal sterilization (Table 9). Freshly harvested 
autologous excised abdominal wall tissue served as the control device. The commercially 
available devices are processed by methods that disrupt cell membranes and cytoplasmic 
organelles, denature cytoplasmic proteins, and largely eliminate these components from the 
remaining ECM.  
Each of the test articles evaluated in this study (excluding autologous abdominal wall 
tissue) was purchased from the respective manufacturer. The handling of the materials after 
removal from the package and prior to surgical implantation was performed according to 
manufacturer’s instructions as provided in the package insert. 
 
Table 9: Source tissue, configuration, and processing methods for each of the five commercially available 
ECM materials. 
 
 
 120 
A.2.3 Animal Model  
An established rat model of abdominal wall repair was used to evaluate the host morphologic 
response to each implanted biomaterial. This model includes muscle and tendon tissue (i.e., the 
musculotendinous junction), the presence of a variable and multidirectional load, and a clinically 
obvious failure outcome (i.e., hernia). All procedures described in this study were performed in 
accordance with the National Institute of Health (NIH) guidelines for care and use of laboratory 
animals. All procedures were approved by the Institutional Animal Care and Use Committee.   
Sprague Dawley rats in the weight range of 300-500 grams were purchased from Charles 
River Laboratories (Wilmington, MA). The animals were housed individually in shoebox cages 
and fed a diet of Purina Iso Pro ad libitum. The bedding was changed at least once per week.  
The animals were examined by a veterinarian prior to surgery and determined to be in good 
health.  The housing environment was maintained at a temperature of 68 to 76° F.   
Each animal was anesthetized with isoflurane (2% in oxygen) in an inhalation chamber. 
The surgical site was clipped, shaved and prepared for sterile surgery with a betadine scrub. 
Sterile technique was used at all times. A ventral midline abdominal incision was made and the 
skin and subcutaneous tissue were separated from the underlying muscle tissues on one side of 
the midline for a distance of approximately 4.0 cm. The incision in the ventral midline of the 
abdominal skin was retracted to expose the ventral lateral wall adjacent to the linea alba, 
including the musculotendinous junction of the abdominal wall musculature.    
A 1.0-cm2 defect of the musculotendinous portion of the ventral lateral abdominal wall 
was excised leaving the underlying transversalus fascia and peritoneum intact. The defect was 
then replaced with a size-matched piece of the test article chosen for that animal. Autologous 
excised abdominal wall tissue served as the control implant. One 4-0 Prolene suture was placed 
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at each of the four corners of the test article to secure attachment to the adjacent abdominal wall 
and to demarcate the implant. Securing the test articles in this manner provided a mechanism by 
which the test article was subjected to the mechanical forces delivered by the adjacent native 
abdominal wall musculature. A total of only four sutures were used for each device to avoid the 
predominance of a host tissue reaction to the suture material rather than the test article. A 
subcuticular placement of 4-0 Vicryl was used to close the skin incision. Each animal was 
recovered from anesthesia on a heating pad and returned to its housing unit.    
Each rat received 0.02 mg Buprenex SQ and 2 mg Gentamicin SQ immediately after 
surgery and for two and three days afterward, respectively. The surgical site was evaluated daily 
for the duration of the study, and any signs of swelling, discoloration, or herniation at the 
operative site were recorded. The dietary habits and general health status of each animal were 
recorded daily. 
On the scheduled date of sacrifice, each rat was anesthetized with Isoflurane (5% in 
oxygen) followed by an intracardiac injection of 5 ml potassium chloride to induce immediate 
cardiac arrest. 
A.2.4 Specimen Collection and Histopathology 
Immediately following euthanasia, the defect site with an equal amount of adjacent native tissue 
was excised, mounted on a fixed support structure, and placed in 10% neutral buffered formalin. 
The specimens were then sectioned through their entire thickness and length, including generous 
amounts of the adjacent normal body wall. The tissues were embedded in paraffin, cut into 6 μm 
thick sections and mounted upon glass slides. Tissues were stained with either H&E or Masson’s 
trichrome stain before coverslipping.   
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Semiquantitative analysis included evaluation of:  1) amount of cellular infiltration, 2) 
presence or absence of multinucleate giant cells, 3) vascularity, and 4) degree of organization of 
the replacement connective tissue. At 40x magnification, the cellular infiltration counts were 
based on ten preselected sites at the host-device interface. Multinucleate giant cells, vascularity, 
and the connective tissue organization were evaluated at the same tissue sites as the cellular 
infiltration counts. The areas surrounding suture placement were avoided as part of the analysis 
because of the potential confounding foreign body response that is typically observed with 
Prolene suture material. The scoring criteria are listed in Table 10. Since specific phenotypic 
markers to distinguish between mononuclear macrophages and lymphoid lineage cells were not 
used in the present study, the generic and more conservative term “mononuclear cells” was used 
in the analysis and in the description of the host response to all test articles. 
 
Table 10: Scoring criteria of the semiquantitative histological analysis*. 
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A.2.5 Statistical Methods 
For each of the four response variables (cellularity, multinucleate giant cells, vascularity, and 
degree of connective tissue organization), ten fields were scored on an integer scale of 0 to 3 
(Table 10). Averages of the ten scores for each animal were the raw data that were analyzed 
statistically using a two-way analysis of variance (ANOVA) model. The factors were type of 
scaffold material with six levels (autologous control graft plus the five biologic scaffold 
materials) and time with seven levels. There were three animals for each type by time treatment 
combination. Although the raw data were not normally distributed, the robustness of the 
ANOVA methods was sufficient to guarantee the validity of the results obtained using this 
methodology.   
A.3 RESULTS 
All but one animal survived the surgical procedure without problems. Three rats developed age 
related problems that required euthanasia prior to the scheduled time.  These 4 rats were replaced 
in the study to maintain an equal n-value for each group and subgroup.   
A.3.1 Histopathologic Findings  
The mean score for the three animals in each group by time treatment combination are provided in  
Table 11. For each response variable, both main effects and the interaction were statistically 
significant with P<0.001 in the analysis of variance.   
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The most intense cellular response was observed with GraftJacket, Restore and CuffPatch 
but the temporal appearance of the cell response differed for each of the test articles. 
Multinucleate giant cells were present at some point during the host response with GraftJacket, 
CuffPatch and Permacol but were never seen with Restore, TissueMend or autologous tissue. 
The most intense vascular response was observed with autologous muscle, Restore and 
CuffPatch, but the appearance of this vascular response differed with respect to time for each of 
the devices. The greatest degree of connective tissue organization at the four-month endpoint 
was seen with the Restore device.  
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Table 11: Mean rounded scores for each group according to time-treatment combination*. 
 
 
A.3.2 Morphologic Findings 
At two days, the grafts were surrounded by a moderate accumulation of neutrophils. At four 
days, the neutrophil and mononuclear cell populations increased in number for all grafts. 
 126 
For the autologous abdominal wall tissue graft, there was progressive necrosis of skeletal 
muscle fibers and an increased number of both neutrophils and mononuclear cells that peaked in 
number at the seven-day timepoint (Figure 43A). Tissue edema and necrosis with complete loss 
of tissue and cellular architecture occurred by fourteen days, at which time there was also new 
collagenous connective tissue deposition and prominent angiogenesis. At twenty-eight days, a 
moderate amount of disorganized connective tissue was present at the implant site, consistent 
with scar tissue formation. Remnants of muscle fibers were scattered randomly throughout the 
tissue with a small number of mononuclear cells. The fifty-six and 112-day timepoints showed 
replacement of the autologous graft by dense, poorly organized collagenous connective tissue 
and scattered islands of adipose tissue. (Figure 43B). 
 
 
Figure 43: Histologic appearance of the autologous tissue graft at (A) seven and (B) 112 days. At seven days, 
necrotic skeletal muscle fiber bundles (*), a dense infiltration of neutrophils, and mononuclear cells were 
present. At 112 days the autograft was replaced by moderately dense scar tissue, characterized by fibrous 
connective tissue and adipose connective tissue. The red-staining muscle fibers at the bottom of the image 
represent the underlying transversalis (Masson’s trichrome, X200, insets, X400). 
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At 7 days, the cellular response for GraftJacket consisted primarily of dense 
accumulations of mononuclear cells (Figure 44A). Occasional multinucleate giant cells 
surrounded the graft site at the 7-day timepoint, and by fourteen days, the cellular infiltrate was 
dense and consisted exclusively of mononuclear cells. The GraftJacket architecture was 
disrupted at the edges of the material with deposition of small amounts of new extracellular 
matrix at fourteen days. By twenty-eight days, the mononuclear cell population increased slightly 
from that observed at fourteen days and a small amount of new host connective tissue was 
present at the edges of the GraftJacket device. Moderate angiogenesis, minimal graft 
degradation, and a prominent cellular infiltrate were observed. By fifty-six days, the new host 
connective tissue at the edges of the graft material was moderately dense, the cellular infiltrate 
had subsided, and the majority of the graft material was unchanged from the appearance of the 
original scaffold article and was not yet infiltrated or populated by cells. At 112 days post 
surgery, there was partial degradation of the GraftJacket device and replacement with dense, 
partially organized collagenous connective tissue (Figure 44B).    
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 Figure 44: Histologic appearance of the GraftJacket device (stained blue) at (A) seven and (B) 112 days after 
surgery. At seven days, a dense mononuclear cell infiltration was limited almost exclusively to the edge of the 
device (arrows). Inset: The arrow represents the lower edge of the GraftJacket-host tissue interface, which is 
bordered by dense, red-staining mononuclear cell infiltrate. At 112 days, there was partial degradation of the 
GraftJacket device, with replacement by moderately organized dense collagenous connective tissue. The 
original device is marked with *, and newly deposited collagenous connective tissue is marked with an arrow 
(Masson’s trichrome, X200, insets, X400). 
 
For the Restore device, the cell population was mostly mononuclear in morphology and 
was distributed throughout the graft material. The individual layers of the Restore device were 
still distinct and identifiable at 7 days but new host-derived ECM was deposited between the 
layers of the original Restore device (Figure 45A). By fourteen days, there was abundant 
angiogenesis and extensive infiltration of the ECM scaffold material by sheets of mononuclear 
cells. A loss of the distinct 10-layer multilaminate device architecture occurring at twenty-eight 
days, and only remnants of the Restore device were still identifiable. By fifty-six days, islands of 
muscle cells and adipose connective tissue cells were found within the implant site and partially 
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organized connective tissue replaced almost the entirety of the Restore device. Nerve cells were 
present on the exterior surface of the implant, and only occasional inflammatory cells could still 
be found at fifty-six days post surgery. By the 112-day timepoint, the vascularity of the implant 
site was still very prominent and the Restore device appeared to be completely degraded and 
replaced with a mixture of organized muscle cells, collagenous connective tissue, and small 
islands of adipose connective tissue (Figure 45B). 
 
 
Figure 45: Histologic appearance of the Restore device (A) seven and (B) 112 days after surgery. At seven 
days, a dense mononuclear cell infiltration separated the individual layers of the device (blue-staining 
material marked with *). At 112 days, the Restore device had been replaced by a vascularized connective 
tissue with islands of skeletal muscle scattered randomly throughout the tissue (arrows) (Masson’s trichrome, 
X200, insets, X400). 
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The CuffPatch device showed an increased neutrophil population by seven days, with a 
moderate amount of tissue edema that extended into the adjacent native abdominal wall tissue 
(Figure 46A). There was minimal infiltration of cells beyond the edges of the test article at 
fourteen days, and new host extracellular matrix and fibrous connective tissue was deposited in 
the space immediately surrounding the implant. Multinucleate giant cells were scattered 
throughout the periphery of the implant site at fourteen and twenty-eight days. By fifty-six days 
post surgery, neutrophils and mononuclear cells separated the individual layers of the CuffPatch 
device in the central regions of the graft site and the vascularity of the surrounding tissue was 
very prominent. Scaffold degradation was apparent by the fifty-six day timepoint, and a robust 
inflammatory cell reaction, primarily mononuclear in nature, infiltrated the entirety of the 
scaffold material. By 112 days, a typical foreign body tissue response was present, including the 
presence of multinucleate giant cells. As seen in Figure 46B, remnants of the originally 
implanted biomaterial were still identifiable with little organization of new host connective tissue 
at the implant site.  
 
 
 131 
 Figure 46: Histologic appearance of the CuffPatch device at (A) seven and (B) 112 days post implantation. At 
seven days, a dense accumulation of neutrophils and mononuclear cells were located primarily at the edge of 
the implanted device (the arrows indicate the edge of CuffPatch, the blue-stained material). The native 
abdominal wall skeletal muscle tissue can be seen in the lower left-hand portion. Inset: The interface between 
the dense cellular accumulation and the edge of the CuffPatch device. 112 days, there were a moderate 
number of inflammatory cells, including multinucleate giant cells (arrow) within the graft site. Remnants of 
the originally implanted CuffPatch device could still be identified (blue material marked with *) (Masson’s 
trichrome, X200, insets, X400). 
 
For the TissueMend device, there was an absence of host cell invasion by seven days, and 
small amounts of fibrous connective tissue were deposited at the periphery of the device (Figure 
47A). The vascularity at the interface between the native host tissue and the TissueMend device 
was increased above that of the surrounding normal tissue and it remained increased for the 
entire 112-day study period. By twenty-eight and fifty-six days post surgery, the fibrous capsule 
had increased in thickness with little infiltration of the TissueMend device by host cells. By 112 
days there was degradation of scaffold material at the edges of the device. Adipose connective 
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tissue accumulated near the borders of the TissueMend device, and a dense, highly organized 
connective tissue capsule was present (Figure 47B).   
 
 
Figure 47: Histologic appearance of the TissueMend device at (A) seven and (B) 112 days after implantation. 
At seven days, there was very little infiltration of the edge of the device by host inflammatory cells (the 
arrows show the lower edge of the TissueMend, the solid blue-stained material). At 112 days, the device-
implant site showed an accumulation of adipose connective tissue (circular white areas) at the edges of the 
TissueMend device (internal to the surrounding capsule, as indicated by the bracket), but the remainder of 
the device (blue materials marked with *) remained virtually unchanged from the time of implantation 
(Masson’s trichrome, X200, insets, X400). 
 
For the Permacol device, poorly organized fibrous connective tissue deposition was noted 
as early as four days. From fourteen to fifty-six days, the fibrous connective tissue capsule 
around the device was the predominant morphologic finding. Small numbers of mononuclear 
cells were present at the edges of the scaffold material and multinucleate giant cells were present 
from 7 days (Figure 48A) until fifty-six days. By fifty-six and 112 days, the host cellular 
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response was minimal. There was almost no evidence for scaffold degradation at the 112-day 
timepoint and a thin fibrous connective tissue capsule surrounded the device (Figure 48B). 
 
 
Figure 48: Histologic appearance of the Permacol device at (A) seven and (B) 112 days after surgery. At seven 
days, there was an accumulation of both neutrophils and mononuclear cells mixed with a thin fibrous capsule 
surrounding the device. The solid blue-staining material above the horizontal line is the Permacol device. 
Inset: Inflammatory cells at the periphery of the Permacol device (*). At 112 days, a dense fibrous tissue 
(brackets) encapsulates the Permacol device (blue staining material located above the bracket). There was 
almost no evidence of scaffold degradation or remodeling (Masson’s trichrome, X200, insets, X400). 
 
A.4 DISCUSSION 
The host tissue response to five different commercially available ECM-based scaffold materials 
and autologous tissue was evaluated in an established rodent model of body wall repair. The 
marketing literature for all devices claims host acceptance and intact functionality. The host 
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response in which all variables were equal showed that there were clear differences in the 
amount and temporal appearance of inflammatory cells, the morphologic structural integrity of 
the devices over time, and the type of host tissue that either replaced or surrounded the ECM-
derived devices. 
The 16-week remodeling outcome of the present study differed markedly between the 
devices. The autologous control tissue showed typical scar tissue formation. The 16-week host 
tissue response to GraftJacket showed replacement of the device with fibrous connective tissue 
and a persistent low-grade chronic inflammatory response. The Restore device was replaced by a 
mixture of muscle cells and organized connective tissue. The CuffPatch device showed a slower 
remodeling process as compared to either the autologous control tissue or Restore. An 
accumulation of dense collagenous tissue and a persistent foreign body response was present at 
the 16-week timepoint. The host response to TissueMend and Permacol was consistent with the 
typical response to a non-resorbable foreign material; that is, a response characterized by low-
grade chronic inflammation, minimal scaffold degradation, and fibrous encapsulation. 
A.5 CONCLUSIONS  
This study represents the first head-to-head comparison of the clinically available ECM scaffold 
materials in an animal model, and showed that the five different scaffold devices currently used 
for musculotendinous repair are distinct with regard to the host tissue response. A limitation of 
the present study is that it was conducted in a rodent model, which may or may not be predictive 
of the response seen in humans.  
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